US20230007916A1 - Analyte monitoring system and methods of use - Google Patents
Analyte monitoring system and methods of use Download PDFInfo
- Publication number
- US20230007916A1 US20230007916A1 US17/868,386 US202217868386A US2023007916A1 US 20230007916 A1 US20230007916 A1 US 20230007916A1 US 202217868386 A US202217868386 A US 202217868386A US 2023007916 A1 US2023007916 A1 US 2023007916A1
- Authority
- US
- United States
- Prior art keywords
- data points
- analyte
- data
- algorithm
- maximum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 162
- 238000012544 monitoring process Methods 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000009499 grossing Methods 0.000 claims abstract description 114
- 238000012545 processing Methods 0.000 claims abstract description 71
- 238000012937 correction Methods 0.000 claims abstract description 62
- 230000008859 change Effects 0.000 claims abstract description 36
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000012377 drug delivery Methods 0.000 claims description 6
- 238000012935 Averaging Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 102
- 239000008103 glucose Substances 0.000 abstract description 102
- 230000004043 responsiveness Effects 0.000 abstract description 6
- 238000007920 subcutaneous administration Methods 0.000 abstract description 2
- 230000006854 communication Effects 0.000 description 25
- 238000004891 communication Methods 0.000 description 25
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 238000005259 measurement Methods 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 210000003722 extracellular fluid Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001133 acceleration Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- -1 e.g. Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 230000007175 bidirectional communication Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48785—Electrical and electronic details of measuring devices for physical analysis of liquid biological material not specific to a particular test method, e.g. user interface or power supply
- G01N33/48792—Data management, e.g. communication with processing unit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0026—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the transmission medium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/683—Means for maintaining contact with the body
- A61B5/6832—Means for maintaining contact with the body using adhesives
- A61B5/6833—Adhesive patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7225—Details of analog processing, e.g. isolation amplifier, gain or sensitivity adjustment, filtering, baseline or drift compensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/002—Monitoring the patient using a local or closed circuit, e.g. in a room or building
Definitions
- Analyte e.g., glucose monitoring systems including continuous and discrete monitoring systems
- a small, lightweight, battery powered and microprocessor controlled system configured to detect signals proportional to the corresponding measured glucose levels using an electrometer and radio frequency (RF) signals to transmit the collected data.
- Certain analyte monitoring systems include a transcutaneous or subcutaneous analyte sensor configuration which is, for example, partially mounted on the skin of a subject whose analyte level is to be monitored.
- the sensor cell may use a two or three-electrode (work, reference, and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.
- the analyte sensor may be configured so that a portion thereof is placed under the skin of the patient so as to detect the analyte levels of the patient, with another segment of the analyte sensor adapted to be in communication with the data processing unit.
- the data processing unit is configured to communicate the analyte levels detected by the sensor over a wireless communication link such as an RF (radio frequency) communication link to a receiver/monitor unit.
- the receiver/monitor unit performs data analysis, among others on the received analyte levels to generate information pertaining to the monitored analyte levels.
- the present disclosure describes embodiments including methods for overcoming sensor noise and lag between the interstitial fluid and blood, both of which can introduce error. Certain embodiments allow for a balance between signal responsiveness and the reduction in noise by a smoothing process. Certain aspects utilize a combination of algorithms, including algorithms optimized to maintain minimal expected error between the final sensor output and a corresponding reference and one that provides more stable rates of change in glucose levels. In certain aspects, lag correction algorithms designed to minimize the correlation between sensor error (with respect to reference blood glucose) and rates of change calculate glucose values with optimal point wise accuracy, and smoothing algorithms to minimize the effect of noise accurately calculate rates of change in glucose levels.
- the present disclosure provides embodiments including methods for monitoring an analyte including monitoring a data stream including a set of contiguous source data points related to the analyte concentration; if a higher sample rate is desired, generating a set of monitored data streams from the set of contiguous source data points, utilizing one or more of the monitored data streams or the set of contiguous source data points to compute a maximum lag correction oriented signal, wherein the lag correction algorithm attempts to eliminate the expected error due to blood-to-interstitial glucose dynamics with reasonable but minimal regard to noise amplification, utilizing one or more of the monitored data streams or the set of contiguous source data points to generate a maximum smoothing oriented signal, wherein the smoothing algorithm attempts to eliminate noise, which includes sample time-to-sample time variation not correlated to true glucose change, utilizing the maximum lag correction oriented signal for generating analyte concentration and utilizing the maximum smoothing oriented signal for generating a rate of change in the analyte concentration.
- Certain embodiments of the present disclosure include methods for monitoring an analyte including monitoring a data stream including a set of contiguous source data points related to the analyte concentration, providing a set of monitored data streams from the set of source data points, wherein each set of monitored data streams is generated utilizing a spline, up-sampling, or regularization algorithm, providing a set of maximum lag corrected signals from the set of monitored data streams, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical monitored data stream data points that minimize the correlation between the expected glucose error and time derivative estimates or minimize the correlation between the expected glucose error and a pre-determined array of historical monitored data stream, providing a set of maximum smoothing signals from the set of monitored data streams, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, generating analyte concentration utilizing the maximum lag corrected signals, and generating a rate of change in the analyte concentration utilizing the maximum smoothing signals.
- rate of change can be computed based on maximum smoothing signals using a variety of methods, including a backwards first difference approximation using the most recent two successive maximum smoothing signals measurements, Finite Impulse Response (FIR) filters employing 2 or more recent maximum smoothing signals measurements, or the slope of a Least Squares Error Fit of a line based on recent maximum smoothing signals measurements.
- FIR Finite Impulse Response
- Certain aspects of the present disclosure include methods for monitoring an analyte including monitoring a data stream including a set of contiguous source data points related to analyte concentration, providing a set of maximum lag corrected signals from the source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points that minimize the correlation between the expected glucose error and time derivative estimates or minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing a set of maximum smoothing signals from the set of source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, generating analyte concentration utilizing the maximum lag corrected signals, and generating a rate of change in the analyte concentration utilizing the maximum smoothing signals.
- aspects of the present disclosure include methods for monitoring an analyte including monitoring a data stream including a set of contiguous source data points related to the analyte concentration, providing a set of maximum lag corrected signals from the set of monitored data stream, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical monitored data stream data points that minimize the correlation between the expected glucose error and time derivative estimates or minimize the correlation between the expected glucose error and a pre-determined array of historical monitored data stream, providing a set of maximum smoothing signals from the set of monitored data stream, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, providing a second set of maximum smoothing signals from the set of monitored data stream, wherein each of the second set of maximum smoothing signals is generated utilizing a smoothing algorithm, generating analyte concentration utilizing a weighted combination of maximum lag corrected signals and maximum smoothing signals, wherein more weight is placed on the set of maximum lag corrected signals to generate the output, and generating a
- Certain aspects of the present disclosure include methods for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to the analyte concentration, providing a set of maximum lag corrected signals from the set of source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points that minimize the correlation between the expected glucose error and time derivative estimates or minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing a set of maximum smoothing signals from the set of source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, generating analyte concentration utilizing a weighted combination of maximum lag corrected signals and maximum smoothing signals, where more weight is placed on the maximum lag corrected signals to generate the output and generating a rate of change in the analyte concentration utilizing a weighted combination of maximum lag corrected signals and maximum smoothing signals, where more weight is placed on the maximum smoothing signals to generate the
- FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system in accordance with certain embodiments of the present disclosure
- analyte e.g., glucose
- FIG. 2 illustrates data related to changes in interstitial fluid measurement and two filtered outputs as compared against discrete blood glucose measurements and an up-sampled or monitored smooth blood glucose signal;
- FIG. 3 illustrates a closer view of a region from FIG. 2 , highlighting data during a rapid rise in glucose level illustrating how each algorithm deals with a rapid rise in glucose level;
- FIG. 4 is a flow chart illustrating certain embodiments for monitoring and processing analyte data
- FIG. 5 is a flow chart illustrating certain embodiments for monitoring and processing analyte data utilizing monitored data stream.
- FIG. 6 is a flow chart illustrating certain embodiments for monitoring and processing analyte data utilizing weighted data processing.
- the present disclosure provides for the utilization of a combination of algorithms to strike a balance between responsiveness and minimizing noise.
- Certain embodiments involve a maximum lag correction algorithm and a maximum smoothing algorithm.
- the lag correcting algorithm minimizes the expected point-wise error of glucose values, resulting in accurate glucose values whereas the smoothing algorithm minimizes the sample time-to-sample time variability which provides rates of change with optimum accuracy.
- the development and use of lag correction algorithms can be found in U.S. Patent Publication Nos. 2010/0191085, now U.S. Pat. No. 8,224,415, 2010/0023291, now U.S. Pat. No. 8,515,517, 2009/0198118, now U.S. Pat. Nos. 8,473,022, and 7,618,369, the disclosures of each of which are incorporated herein by reference for all purposes.
- algorithms compensate for lag between blood glucose (BG) and interstitial glucose (IG), measured by a sensor, by correlating time derivatives (e.g. rate estimate, acceleration estimate, band limited rate estimate, etc.) with the BG to IG discrepancy, correlating a pre-determined array of historical sensor data with the BG to IG discrepancy, and providing cancellation terms computed from the sensor signal.
- time derivatives e.g. rate estimate, acceleration estimate, band limited rate estimate, etc.
- lag correction algorithms selected vary in aggressiveness in order to strike a balance between levels of responsiveness and smoothing.
- a lag correction algorithm is deemed more aggressive when it attempts to remove the average error correlated to blood-to-interstitial glucose dynamics with less regard to the noise amplification effect it generates.
- a lag correction algorithm is overly aggressive if the amount of lag correction exceeds the required amount, resulting in an error of the opposite sign as compared to when no lag correction is attempted.
- a lag correction algorithm is deemed less aggressive if the amount of correction is somewhere between the optimal amount and no lag correction at all.
- the combination of a lag correcting algorithm in combination with a smoothing algorithm can similarly be used to provide more accurate acceleration data in combination with representative glucose values.
- FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system in accordance with certain embodiments of the present disclosure.
- an analyte e.g., glucose
- FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system in accordance with certain embodiments of the present disclosure.
- analyte e.g., glucose
- Analytes that may be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin.
- concentration of drugs such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.
- the analyte monitoring system 100 includes a sensor 101 , a data processing unit (e.g., sensor electronics) 102 connectable to the sensor 101 , and a primary receiver unit 104 which is configured to communicate with the data processing unit 102 via a communication link 103 .
- the sensor 101 and the data processing unit (sensor electronics) 102 may be configured as a single integrated assembly 110 .
- the integrated sensor and sensor electronics assembly 110 may be configured as an on-body patch device.
- the on-body patch device may be configured for, for example, RFID or RF communication with a reader device/receiver unit, and/or an insulin pump.
- the primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 to evaluate or otherwise process or format data received by the primary receiver unit 104 .
- the data processing terminal 105 may be configured to receive data directly from the data processing unit 102 via a communication link which may optionally be configured for bi-directional communication.
- the data processing unit 102 may include a data processing unit or a transceiver to transmit and/or receive data to and/or from the primary receiver unit 104 , the data processing terminal 105 or optionally the secondary receiver unit 106 .
- an optional secondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from the data processing unit 102 .
- the secondary receiver unit 106 may be configured to communicate with the primary receiver unit 104 , as well as the data processing terminal 105 .
- the secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105 .
- the secondary receiver unit 106 may be a de-featured receiver as compared to the primary receiver unit 104 , i.e., the secondary receiver unit 106 may include a limited or minimal number of functions and features as compared with the primary receiver unit 104 .
- the secondary receiver unit 106 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device such as a wrist watch, arm band, etc., for example.
- the secondary receiver unit 106 may be configured with the same or substantially similar functions and features as the primary receiver unit 104 .
- the secondary receiver unit 106 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or bi-directional communication device.
- analyte monitoring system 100 may include more than one sensor 101 and/or more than one data processing unit 102 , and/or more than one data processing terminal 105 .
- the analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system.
- each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within the analyte monitoring system 100 .
- unique IDs, communication channels, and the like may be used.
- the senor 101 is physically positioned in or on the body of a user whose analyte level is being monitored.
- the sensor 101 may be configured to at least process send data related to its configuration into a corresponding signal for transmission by the data processing unit 102 .
- the data processing unit 102 is coupleable to the sensor 101 so that both devices are positioned in or on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously.
- the data processing unit 102 in certain embodiments may include a portion of the sensor 101 (proximal section of the sensor in electrical communication with the data processing unit 102 ) which is encapsulated within or on the printed circuit board of the data processing unit 102 with, for example, potting material or other protective material.
- the data processing unit 102 performs data processing functions, where such functions may include but are not limited to, filtering and encoding of data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103 .
- the sensor 101 or the data processing unit 102 or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user.
- the primary receiver unit 104 may include an analog interface section including an RF receiver and an antenna that is configured to communicate with the data processing unit 102 via the communication link 103 , and a data processing section for processing the received data from the data processing unit 102 such as data decoding, error detection and correction, data clock generation, and/or data bit recovery.
- the primary receiver unit 104 in certain embodiments is configured to synchronize with the data processing unit 102 to uniquely identify the data processing unit 102 , based on, for example, an identification information of the data processing unit 102 , and thereafter, to periodically receive signals transmitted from the data processing unit 102 associated with the monitored analyte levels detected by the sensor 101 . That is, when operating in the CGM mode, the receiver unit 104 in certain embodiments is configured to automatically receive data related to the configuration of the sensor from the analyte sensor/sensor electronics when the communication link (e.g., RF range) is maintained or opened between these components.
- the communication link e.g., RF range
- the data processing terminal 105 may include a personal computer, portable data processing devices or computers such as a laptop computer or a handheld device (e.g., personal digital assistants (PDAs), communication devices such as a cellular phone (e.g., a multimedia and Internet-enabled mobile phone such as an iPhone, a Blackberry device, a Palm device such as Palm Pre, Treo, or similar phone), mp3 player, pager, and the like), drug delivery device, insulin pump, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown).
- PDAs personal digital assistants
- communication devices such as a cellular phone (e.g., a multimedia and Internet-enabled mobile phone such as an iPhone, a Blackberry device, a Palm device such as Palm Pre, Treo, or similar phone), mp3 player, pager, and the like), drug delivery device, insulin pump, each of which may be configured for data communication with
- the data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the primary receiver unit 104 for receiving, among others, the measured analyte level or configuration data.
- the primary receiver unit 104 may be configured to integrate an infusion device therein so that the primary receiver unit 104 is configured to administer insulin (or other appropriate drug) therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the data processing unit 102 .
- An infusion device may be an external device or an internal device (wholly implantable in a user).
- the data processing terminal 105 which may include an insulin pump, may be configured to receive the configuration signals from the data processing unit 102 , and thus, incorporate the functions of the primary receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring.
- the communication link 103 as well as one or more of the other communication interfaces shown in FIG. 1 may use one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements) while avoiding potential data collision and interference.
- the analyte monitoring system may include an on-body patch device with a thin profile that can be worn on the arm or other locations on the body (and under clothing worn by the user or the patient), the on-body patch device including an analyte sensor and circuitry and components for operating the sensor and processing and storing signals, including configuration signals, received from the sensor as well as for communication with the reader device.
- the on-body patch device may include electronics to sample the voltage signal received from the analyte sensor in fluid contact with the body fluid, and to process the sampled voltage signals into the corresponding glucose values and/or store the sampled voltage signal as raw data, or to send configuration information as a signal or data.
- FIG. 2 illustrates data related to changes in blood glucose levels and related data generated from an interstitial fluid measurement, such as interstitial fluid measurements taken by the analyte monitoring system of FIG. 1 , processed utilizing an aggressive lag correction algorithm and a smoothing algorithm.
- Lag from blood glucose (BG) to interstitial glucose (IG) is illustrated in FIG. 2 .
- the raw sensor signal measures glucose concentration in the interstitial fluid space.
- BG reference collected at a slower sample rate is up-sampled as BG proxy to visually match the raw sensor's sample time.
- Both the BG and BG proxy data are only used to provide context on some of the characteristics of IG compared to BG. Neither the BG nor BG proxy data are needed for the methods described in this invention.
- IG levels match BG well provided that glucose concentrations remain steady. Otherwise, IG levels are generally lower than BG while glucose increases, and higher while glucose decreases. From a point-wise perspective, this reduced responsiveness manifests itself as one source of sensor error. However, any attempt to correct for this lag results in the amplification of noise, as can be seen in the maximum lag correction line (curve F in FIG. 2 ). Even in the absence of lag correction, it may be necessary to process the sensor signal to filter out noise.
- a smoothed IG signal is shown to reduce the sample time-to-sample time fluctuations, but further increases the overall BG to IG lag, which is especially visible in curve E in FIG. 2 while glucose is increasing.
- smoothing implies the reduction of sample time-to-sample time fluctuations, but does not require the process to be limited to a retrospective operation.
- the first curve A represents raw sensor data.
- BG measurements B are up-sampled into a smooth curve C in order to visually demonstrate a more fluid progression of BG data.
- a meal event D is shown to increase glucose.
- the fifth curve E represents data processed with a smoothing curve.
- the sixth curve F provides output that is close to the blood glucose levels represented by curve C.
- Raw sensor signal is collected at a pre-determined time interval (e.g. once every 1 minute) where the signal is either: (a) pre filtered at a much faster time interval and/or processed to remove erroneous data or (b) a direct sampling from the source without any preprocessing. Blood glucose is also collected at a longer time interval (e.g. once every 15 minutes) to provide reference data.
- a smooth BG proxy is generated from the BG reference at a sample interval and time points that match the pre-determined time interval of the collected sensor signal. Both the BG and BG proxy data are only used to provide context, and are not needed for the methods described in this invention.
- a meal event initiates a rise in the patient's BG level. Maximizing the signal noise filtering is shown to produce a smoother signal at the expense of additional lag. On the other hand, maximizing lag correction allows for better point-wise agreement with BG at the expense of additional sample-to-sample variation.
- FIG. 3 illustrates a closer view of a region (73.0 to 73.7 units of elapsed time) from FIG. 2 , highlighting data during a rapid rise in glucose level illustrating how each algorithm deals with a rapid rise in glucose level.
- the highlighted region of FIG. 2 provided in FIG. 3 , focuses on a region of rapid increase in glucose and illustrates the different way each algorithm responds.
- curve E generated without any lag correction, provides more accurate rate of change data because its trend matches well with that of the trend of curve C, but provides less accurate data regarding glucose concentration.
- curve F generated with lag correction produces data output regarding glucose levels during the rapid increase in glucose levels that closely corresponds to curve C, representing actual blood glucose data.
- aspects of the present disclosure provide for the utilization of the combination of a lag correction algorithm and a smoothing algorithm in a continuous glucose monitoring system to optimize the accuracy of readings related to glucose levels and the rates of change in glucose levels.
- the achievement of better accuracy for readings of both glucose level and its rate of change is important in first understanding the real changes in blood glucose and properly managing its level.
- FIG. 4 is a flow chart illustrating certain embodiments for monitoring and processing analyte data.
- a processing unit such as data processing unit 102 or receiver unit 104 of the analyte monitoring system 100 of FIG. 1 , receives data related to an analyte concentration ( 410 ), which may be received from a sensor, such as sensor 101 of analyte monitoring system 100 of FIG. 1 .
- the received data is analyzed and a maximum lag corrected signal is generated ( 420 ).
- the maximum lag corrected signal is generated by utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points.
- the maximum lag correction signal is generated by utilizing an aggressive lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero.
- the maximum lag corrected signal is analyzed to determine a corrected analyte concentration ( 440 ).
- the received data is also analyzed and a maximum smoothing signal is generated ( 430 ) by applying a smoothing algorithm to the received data and the maximum smoothing signal is analyzed to determine the rate of change of the monitored analyte level ( 450 ).
- FIG. 5 is a flow chart illustrating certain embodiments for monitoring and processing analyte data utilizing monitored data stream.
- a processing unit such as data processing unit 102 or receiver unit 104 of the analyte monitoring system 100 of FIG. 1 , receives data related to an analyte concentration ( 510 ), which may be received from a sensor, such as sensor 101 of analyte monitoring system 100 of FIG. 1 .
- the received data is sampled at a high speed to generate a monitored data stream ( 520 ).
- the monitored data stream is optionally generated utilizing a spline, up-sampling, or regularization algorithm.
- the monitored data stream is analyzed and a maximum lag corrected signal is generated ( 530 ).
- the maximum lag corrected signal is generated by utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points.
- the maximum lag correction signal is generated by utilizing an aggressive lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero.
- the maximum lag corrected signal is analyzed to determine a corrected analyte concentration ( 550 ).
- the received data is also analyzed and a maximum smoothing signal is generated ( 540 ) by applying a smoothing algorithm to the received data and the maximum smoothing signal is analyzed to determine the rate of change of the monitored analyte level ( 560 ).
- FIG. 6 is a flow chart illustrating certain embodiments for monitoring and processing analyte data utilizing weighted data processing.
- a processing unit such as data processing unit 102 or receiver unit 104 of the analyte monitoring system 100 of FIG. 1 , receives data related to an analyte concentration ( 610 ), which may be received from a sensor, such as sensor 101 of analyte monitoring system 100 of FIG. 1 .
- the received data is analyzed and a maximum lag corrected signal is generated ( 620 ).
- the maximum lag corrected signal is generated by utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points.
- the maximum lag correction signal is generated by utilizing an aggressive lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero.
- the received data is also analyzed and a maximum smoothing signal is generated ( 630 ) by applying a smoothing algorithm to the received data.
- both signals are analyzed and weighted to determine the analyte concentration ( 640 ) and rate of change of the monitored analyte level ( 650 ).
- the analyte concentration determination is made by weighting the maximum lag corrected signal more heavily than the maximum smoothing signal and the rate of change determination is made by weighting the maximum smoothing signal more heavily than the maximum lag corrected signal.
- a method for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to the concentration of an analyte, providing one or more sets of maximum lag corrected signals from the one or more sets of monitored data stream, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical monitored data stream data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical monitored data stream, providing one or more sets of maximum smoothing signals from the set of monitored data stream, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, determining analyte concentration utilizing the one or more sets of maximum lag corrected signals, and determining a rate of change in the analyte concentration utilizing the one or more sets of maximum smoothing signals.
- providing the one or more sets of maximum lag corrected signals includes utilizing an aggressive lag correction algorithm, the lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero.
- monitoring a data stream including a set of contiguous source data points related to the analyte concentration includes monitoring a data stream received from a transcutaneously positioned analyte sensor, where the transcutaneously positioned analyte sensor in certain embodiments is operatively coupled to a continuous glucose monitoring system.
- one or more sets of maximum smoothing signals are further utilized to determine acceleration data of the analyte concentration.
- a method for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to analyte concentration, providing one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, determining analyte concentration utilizing the one or more sets of maximum lag corrected signals, and determining a rate of change in the analyte concentration utilizing the one or more sets of maximum smoothing signals.
- a method for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to analyte concentration, providing one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, determining analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the one or more sets of maximum smoothing signals, wherein more weight is placed on the one or more sets of maximum lag corrected signals to determine the analyte concentration, and
- a method for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to analyte concentration, providing one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing a first one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, providing a second one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each of the second set of maximum smoothing signals is generated utilizing a second smoothing algorithm, determining analyte concentration utilizing a weighted combination of the one or more sets
- the first smoothing algorithm and the second smoothing algorithm are different.
- the method further includes averaging the first one or more sets of maximum smoothing signals and the second one or more sets of maximum smoothing signals.
- An apparatus in accordance with another embodiment includes one or more processors, and a memory storing instructions which, when executed by the one or more processors, causes the one or more processors to monitor a data stream including a set of contiguous source data points related to the concentration of an analyte, to provide one or more sets of monitored data stream from the set of contiguous source data points, wherein each set of monitored data stream is generated utilizing a spline, up-sampling, or regularization algorithm, to provide one or more sets of maximum lag corrected signals from the one or more sets of monitored data stream, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical monitored data stream data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical monitored data stream, to provide one or more sets of maximum smoothing signals from the set of monitored data stream, wherein each set of maximum smoothing signals is generated utilizing a smoothing
- the instructions to provide the one or more sets of maximum lag corrected signals include instructions to utilize an aggressive lag correction algorithm, the lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero.
- the instructions to monitor the data stream including the set of contiguous source data points related to the analyte concentration includes instructions to monitor a data stream received from a transcutaneously positioned analyte sensor operatively coupled to the one or more processors.
- the one or more sets of maximum smoothing signals are further utilized to determine acceleration data of the analyte concentration.
- An apparatus in accordance with another embodiment includes one or more processors, and a memory storing instructions which, when executed by the one or more processors, causes the one or more processors to monitor a data stream including a set of contiguous source data points related to analyte concentration, to provide one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, to provide one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, to determine analyte concentration utilizing the one or more sets of maximum lag corrected signals and to determine a rate of change in the analyte concentration utilizing the one or more sets of maximum smoothing signals.
- An apparatus in accordance with still another embodiment includes one or more processors, and a memory storing instructions which, when executed by the one or more processors, causes the one or more processors to monitor a data stream including a set of contiguous source data points related to analyte concentration, to providing one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, to provide one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, to determine analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the one or more sets of maximum smoothing signals, wherein more weight is placed on the one or
- An apparatus in accordance with still yet another embodiment includes one or more processors, and a memory storing instructions which, when executed by the one or more processors, causes the one or more processors to monitor a data stream including a set of contiguous source data points related to analyte concentration, to provide one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, to provide a first one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, to provide a second one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each of the second set of maximum smoothing signals is generated utilizing a second smoothing
- the first smoothing algorithm and the second smoothing algorithm are different.
- Certain embodiment includes instructions to average the first one or more sets of maximum smoothing signals and the second one or more sets of maximum smoothing signals.
Abstract
The present disclosure provides methods of processing data provided by a transcutaneous or subcutaneous analyte sensor utilizing different algorithms to strike a balance between signal responsiveness accompanied by signal noise and the introduction of error associated with that noise. The methods utilize the strengths of a lag correction algorithm and a smoothing algorithm to optimize the quality and value of the resulting data (glucose concentrations and the rates of change in glucose concentrations) to a continuous glucose monitoring system. Also provided are systems and kits.
Description
- The present application is a continuation of U.S. patent application Ser. No. 13/683,996 filed Nov. 21, 2012, now U.S. Pat. No. 9,339,217, which claims priority to U.S. Provisional Application No. 61/563,743, filed Nov. 25, 2011, entitled “Analyte Monitoring System and Methods of Use”, the disclosures of each of which are incorporated by reference for all purposes.
- Analyte, e.g., glucose monitoring systems including continuous and discrete monitoring systems, generally include a small, lightweight, battery powered and microprocessor controlled system configured to detect signals proportional to the corresponding measured glucose levels using an electrometer and radio frequency (RF) signals to transmit the collected data. Certain analyte monitoring systems include a transcutaneous or subcutaneous analyte sensor configuration which is, for example, partially mounted on the skin of a subject whose analyte level is to be monitored. The sensor cell may use a two or three-electrode (work, reference, and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.
- The analyte sensor may be configured so that a portion thereof is placed under the skin of the patient so as to detect the analyte levels of the patient, with another segment of the analyte sensor adapted to be in communication with the data processing unit. The data processing unit is configured to communicate the analyte levels detected by the sensor over a wireless communication link such as an RF (radio frequency) communication link to a receiver/monitor unit. The receiver/monitor unit performs data analysis, among others on the received analyte levels to generate information pertaining to the monitored analyte levels.
- For systems that calculate the blood glucose concentration by measuring interstitial glucose in real time, lag between the interstitial glucose and blood glucose and sensor noise can introduce error, some of which is detrimental to obtaining accurate glucose and glucose rate of change data.
- It would be desirable to have a method and system to account for lag and system noise and provide robust and useful data that is relevant to the blood glucose system.
- The present disclosure describes embodiments including methods for overcoming sensor noise and lag between the interstitial fluid and blood, both of which can introduce error. Certain embodiments allow for a balance between signal responsiveness and the reduction in noise by a smoothing process. Certain aspects utilize a combination of algorithms, including algorithms optimized to maintain minimal expected error between the final sensor output and a corresponding reference and one that provides more stable rates of change in glucose levels. In certain aspects, lag correction algorithms designed to minimize the correlation between sensor error (with respect to reference blood glucose) and rates of change calculate glucose values with optimal point wise accuracy, and smoothing algorithms to minimize the effect of noise accurately calculate rates of change in glucose levels.
- The present disclosure provides embodiments including methods for monitoring an analyte including monitoring a data stream including a set of contiguous source data points related to the analyte concentration; if a higher sample rate is desired, generating a set of monitored data streams from the set of contiguous source data points, utilizing one or more of the monitored data streams or the set of contiguous source data points to compute a maximum lag correction oriented signal, wherein the lag correction algorithm attempts to eliminate the expected error due to blood-to-interstitial glucose dynamics with reasonable but minimal regard to noise amplification, utilizing one or more of the monitored data streams or the set of contiguous source data points to generate a maximum smoothing oriented signal, wherein the smoothing algorithm attempts to eliminate noise, which includes sample time-to-sample time variation not correlated to true glucose change, utilizing the maximum lag correction oriented signal for generating analyte concentration and utilizing the maximum smoothing oriented signal for generating a rate of change in the analyte concentration.
- Certain embodiments of the present disclosure include methods for monitoring an analyte including monitoring a data stream including a set of contiguous source data points related to the analyte concentration, providing a set of monitored data streams from the set of source data points, wherein each set of monitored data streams is generated utilizing a spline, up-sampling, or regularization algorithm, providing a set of maximum lag corrected signals from the set of monitored data streams, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical monitored data stream data points that minimize the correlation between the expected glucose error and time derivative estimates or minimize the correlation between the expected glucose error and a pre-determined array of historical monitored data stream, providing a set of maximum smoothing signals from the set of monitored data streams, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, generating analyte concentration utilizing the maximum lag corrected signals, and generating a rate of change in the analyte concentration utilizing the maximum smoothing signals. In certain aspects, rate of change can be computed based on maximum smoothing signals using a variety of methods, including a backwards first difference approximation using the most recent two successive maximum smoothing signals measurements, Finite Impulse Response (FIR) filters employing 2 or more recent maximum smoothing signals measurements, or the slope of a Least Squares Error Fit of a line based on recent maximum smoothing signals measurements.
- Certain aspects of the present disclosure include methods for monitoring an analyte including monitoring a data stream including a set of contiguous source data points related to analyte concentration, providing a set of maximum lag corrected signals from the source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points that minimize the correlation between the expected glucose error and time derivative estimates or minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing a set of maximum smoothing signals from the set of source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, generating analyte concentration utilizing the maximum lag corrected signals, and generating a rate of change in the analyte concentration utilizing the maximum smoothing signals.
- Aspects of the present disclosure include methods for monitoring an analyte including monitoring a data stream including a set of contiguous source data points related to the analyte concentration, providing a set of maximum lag corrected signals from the set of monitored data stream, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical monitored data stream data points that minimize the correlation between the expected glucose error and time derivative estimates or minimize the correlation between the expected glucose error and a pre-determined array of historical monitored data stream, providing a set of maximum smoothing signals from the set of monitored data stream, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, providing a second set of maximum smoothing signals from the set of monitored data stream, wherein each of the second set of maximum smoothing signals is generated utilizing a smoothing algorithm, generating analyte concentration utilizing a weighted combination of maximum lag corrected signals and maximum smoothing signals, wherein more weight is placed on the set of maximum lag corrected signals to generate the output, and generating a rate of change in the analyte concentration utilizing a weighted combination of maximum lag corrected signals and maximum smoothing signals, where more weight is placed on the maximum smoothing signals to generate the output.
- Certain aspects of the present disclosure include methods for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to the analyte concentration, providing a set of maximum lag corrected signals from the set of source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points that minimize the correlation between the expected glucose error and time derivative estimates or minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing a set of maximum smoothing signals from the set of source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, generating analyte concentration utilizing a weighted combination of maximum lag corrected signals and maximum smoothing signals, where more weight is placed on the maximum lag corrected signals to generate the output and generating a rate of change in the analyte concentration utilizing a weighted combination of maximum lag corrected signals and maximum smoothing signals, where more weight is placed on the maximum smoothing signals to generate the output.
-
FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system in accordance with certain embodiments of the present disclosure; -
FIG. 2 illustrates data related to changes in interstitial fluid measurement and two filtered outputs as compared against discrete blood glucose measurements and an up-sampled or monitored smooth blood glucose signal; -
FIG. 3 illustrates a closer view of a region fromFIG. 2 , highlighting data during a rapid rise in glucose level illustrating how each algorithm deals with a rapid rise in glucose level; -
FIG. 4 is a flow chart illustrating certain embodiments for monitoring and processing analyte data; -
FIG. 5 is a flow chart illustrating certain embodiments for monitoring and processing analyte data utilizing monitored data stream; and -
FIG. 6 is a flow chart illustrating certain embodiments for monitoring and processing analyte data utilizing weighted data processing. - Before the present disclosure is further described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
- As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, exemplary methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
- As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
- The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
- The present disclosure provides for the utilization of a combination of algorithms to strike a balance between responsiveness and minimizing noise. Certain embodiments involve a maximum lag correction algorithm and a maximum smoothing algorithm. The lag correcting algorithm minimizes the expected point-wise error of glucose values, resulting in accurate glucose values whereas the smoothing algorithm minimizes the sample time-to-sample time variability which provides rates of change with optimum accuracy. The development and use of lag correction algorithms can be found in U.S. Patent Publication Nos. 2010/0191085, now U.S. Pat. No. 8,224,415, 2010/0023291, now U.S. Pat. No. 8,515,517, 2009/0198118, now U.S. Pat. Nos. 8,473,022, and 7,618,369, the disclosures of each of which are incorporated herein by reference for all purposes.
- In certain embodiments, algorithms compensate for lag between blood glucose (BG) and interstitial glucose (IG), measured by a sensor, by correlating time derivatives (e.g. rate estimate, acceleration estimate, band limited rate estimate, etc.) with the BG to IG discrepancy, correlating a pre-determined array of historical sensor data with the BG to IG discrepancy, and providing cancellation terms computed from the sensor signal. These algorithms can improve aggregate point wise accuracy of a continuous glucose monitoring system relative to blood glucose values. However, a consequence of the improved responsiveness is an increased susceptibility to noise due to the amplification of errors caused by noise in the time derivative calculations that are necessary to produce a rate estimate. To better estimate the rate of change, algorithms can be developed that smooth recent data to remove artifacts from noise.
- In certain embodiments, lag correction algorithms selected vary in aggressiveness in order to strike a balance between levels of responsiveness and smoothing. A lag correction algorithm is deemed more aggressive when it attempts to remove the average error correlated to blood-to-interstitial glucose dynamics with less regard to the noise amplification effect it generates. A lag correction algorithm is overly aggressive if the amount of lag correction exceeds the required amount, resulting in an error of the opposite sign as compared to when no lag correction is attempted. A lag correction algorithm is deemed less aggressive if the amount of correction is somewhere between the optimal amount and no lag correction at all.
- The combination of a lag correcting algorithm in combination with a smoothing algorithm can similarly be used to provide more accurate acceleration data in combination with representative glucose values.
-
FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system in accordance with certain embodiments of the present disclosure. Embodiments of the subject disclosure are described primarily with respect to glucose monitoring devices and systems, and methods of using two or more devices in a glucose monitoring system to determine the compatibility of one or more devices in the glucose monitoring system. - Analytes that may be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.
- Referring to
FIG. 1 , the analyte monitoring system 100 includes a sensor 101, a data processing unit (e.g., sensor electronics) 102 connectable to the sensor 101, and a primary receiver unit 104 which is configured to communicate with the data processing unit 102 via a communication link 103. In aspects of the present disclosure, the sensor 101 and the data processing unit (sensor electronics) 102 may be configured as a single integrated assembly 110. In certain embodiments, the integrated sensor and sensor electronics assembly 110 may be configured as an on-body patch device. In such embodiments, the on-body patch device may be configured for, for example, RFID or RF communication with a reader device/receiver unit, and/or an insulin pump. - In certain embodiments, the primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 to evaluate or otherwise process or format data received by the primary receiver unit 104. The data processing terminal 105 may be configured to receive data directly from the data processing unit 102 via a communication link which may optionally be configured for bi-directional communication. Further, the data processing unit 102 may include a data processing unit or a transceiver to transmit and/or receive data to and/or from the primary receiver unit 104, the data processing terminal 105 or optionally the secondary receiver unit 106.
- Also shown in
FIG. 1 is an optional secondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from the data processing unit 102. The secondary receiver unit 106 may be configured to communicate with the primary receiver unit 104, as well as the data processing terminal 105. The secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105. As discussed in further detail below, in certain embodiments the secondary receiver unit 106 may be a de-featured receiver as compared to the primary receiver unit 104, i.e., the secondary receiver unit 106 may include a limited or minimal number of functions and features as compared with the primary receiver unit 104. As such, the secondary receiver unit 106 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device such as a wrist watch, arm band, etc., for example. Alternatively, the secondary receiver unit 106 may be configured with the same or substantially similar functions and features as the primary receiver unit 104. The secondary receiver unit 106 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or bi-directional communication device. - Only one sensor 101, data processing unit 102 and data processing terminal 105 are shown in the embodiment of the analyte monitoring system 100 illustrated in
FIG. 1 . However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system 100 may include more than one sensor 101 and/or more than one data processing unit 102, and/or more than one data processing terminal 105. - The analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within the analyte monitoring system 100. For example, unique IDs, communication channels, and the like, may be used.
- In certain embodiments, the sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor 101 may be configured to at least process send data related to its configuration into a corresponding signal for transmission by the data processing unit 102.
- The data processing unit 102 is coupleable to the sensor 101 so that both devices are positioned in or on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously. The data processing unit 102 in certain embodiments may include a portion of the sensor 101 (proximal section of the sensor in electrical communication with the data processing unit 102) which is encapsulated within or on the printed circuit board of the data processing unit 102 with, for example, potting material or other protective material. The data processing unit 102 performs data processing functions, where such functions may include but are not limited to, filtering and encoding of data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103. In one embodiment, the sensor 101 or the data processing unit 102 or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user.
- In one aspect, the primary receiver unit 104 may include an analog interface section including an RF receiver and an antenna that is configured to communicate with the data processing unit 102 via the communication link 103, and a data processing section for processing the received data from the data processing unit 102 such as data decoding, error detection and correction, data clock generation, and/or data bit recovery.
- In operation, the primary receiver unit 104 in certain embodiments is configured to synchronize with the data processing unit 102 to uniquely identify the data processing unit 102, based on, for example, an identification information of the data processing unit 102, and thereafter, to periodically receive signals transmitted from the data processing unit 102 associated with the monitored analyte levels detected by the sensor 101. That is, when operating in the CGM mode, the receiver unit 104 in certain embodiments is configured to automatically receive data related to the configuration of the sensor from the analyte sensor/sensor electronics when the communication link (e.g., RF range) is maintained or opened between these components.
- Referring again to
FIG. 1 , the data processing terminal 105 may include a personal computer, portable data processing devices or computers such as a laptop computer or a handheld device (e.g., personal digital assistants (PDAs), communication devices such as a cellular phone (e.g., a multimedia and Internet-enabled mobile phone such as an iPhone, a Blackberry device, a Palm device such as Palm Pre, Treo, or similar phone), mp3 player, pager, and the like), drug delivery device, insulin pump, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown). - The data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the primary receiver unit 104 for receiving, among others, the measured analyte level or configuration data. Alternatively, the primary receiver unit 104 may be configured to integrate an infusion device therein so that the primary receiver unit 104 is configured to administer insulin (or other appropriate drug) therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the data processing unit 102. An infusion device may be an external device or an internal device (wholly implantable in a user).
- In particular embodiments, the data processing terminal 105, which may include an insulin pump, may be configured to receive the configuration signals from the data processing unit 102, and thus, incorporate the functions of the primary receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring. In certain embodiments, the communication link 103 as well as one or more of the other communication interfaces shown in
FIG. 1 may use one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements) while avoiding potential data collision and interference. - The analyte monitoring system may include an on-body patch device with a thin profile that can be worn on the arm or other locations on the body (and under clothing worn by the user or the patient), the on-body patch device including an analyte sensor and circuitry and components for operating the sensor and processing and storing signals, including configuration signals, received from the sensor as well as for communication with the reader device. For example, one aspect of the on-body patch device may include electronics to sample the voltage signal received from the analyte sensor in fluid contact with the body fluid, and to process the sampled voltage signals into the corresponding glucose values and/or store the sampled voltage signal as raw data, or to send configuration information as a signal or data.
-
FIG. 2 illustrates data related to changes in blood glucose levels and related data generated from an interstitial fluid measurement, such as interstitial fluid measurements taken by the analyte monitoring system ofFIG. 1 , processed utilizing an aggressive lag correction algorithm and a smoothing algorithm. Lag from blood glucose (BG) to interstitial glucose (IG) is illustrated inFIG. 2 . The raw sensor signal measures glucose concentration in the interstitial fluid space. BG reference collected at a slower sample rate is up-sampled as BG proxy to visually match the raw sensor's sample time. Both the BG and BG proxy data are only used to provide context on some of the characteristics of IG compared to BG. Neither the BG nor BG proxy data are needed for the methods described in this invention. IG levels match BG well provided that glucose concentrations remain steady. Otherwise, IG levels are generally lower than BG while glucose increases, and higher while glucose decreases. From a point-wise perspective, this reduced responsiveness manifests itself as one source of sensor error. However, any attempt to correct for this lag results in the amplification of noise, as can be seen in the maximum lag correction line (curve F inFIG. 2 ). Even in the absence of lag correction, it may be necessary to process the sensor signal to filter out noise. A smoothed IG signal is shown to reduce the sample time-to-sample time fluctuations, but further increases the overall BG to IG lag, which is especially visible in curve E inFIG. 2 while glucose is increasing. The term smoothing implies the reduction of sample time-to-sample time fluctuations, but does not require the process to be limited to a retrospective operation. - Referring to
FIG. 2 , the first curve A represents raw sensor data. BG measurements B are up-sampled into a smooth curve C in order to visually demonstrate a more fluid progression of BG data. A meal event D is shown to increase glucose. The fifth curve E represents data processed with a smoothing curve. The sixth curve F provides output that is close to the blood glucose levels represented by curve C. Raw sensor signal is collected at a pre-determined time interval (e.g. once every 1 minute) where the signal is either: (a) pre filtered at a much faster time interval and/or processed to remove erroneous data or (b) a direct sampling from the source without any preprocessing. Blood glucose is also collected at a longer time interval (e.g. once every 15 minutes) to provide reference data. A smooth BG proxy is generated from the BG reference at a sample interval and time points that match the pre-determined time interval of the collected sensor signal. Both the BG and BG proxy data are only used to provide context, and are not needed for the methods described in this invention. A meal event initiates a rise in the patient's BG level. Maximizing the signal noise filtering is shown to produce a smoother signal at the expense of additional lag. On the other hand, maximizing lag correction allows for better point-wise agreement with BG at the expense of additional sample-to-sample variation. -
FIG. 3 illustrates a closer view of a region (73.0 to 73.7 units of elapsed time) fromFIG. 2 , highlighting data during a rapid rise in glucose level illustrating how each algorithm deals with a rapid rise in glucose level. The highlighted region ofFIG. 2 , provided inFIG. 3 , focuses on a region of rapid increase in glucose and illustrates the different way each algorithm responds. For example, during the rapid increase in glucose, curve E, generated without any lag correction, provides more accurate rate of change data because its trend matches well with that of the trend of curve C, but provides less accurate data regarding glucose concentration. In contrast, curve F generated with lag correction produces data output regarding glucose levels during the rapid increase in glucose levels that closely corresponds to curve C, representing actual blood glucose data. - Aspects of the present disclosure provide for the utilization of the combination of a lag correction algorithm and a smoothing algorithm in a continuous glucose monitoring system to optimize the accuracy of readings related to glucose levels and the rates of change in glucose levels. The achievement of better accuracy for readings of both glucose level and its rate of change is important in first understanding the real changes in blood glucose and properly managing its level.
-
FIG. 4 is a flow chart illustrating certain embodiments for monitoring and processing analyte data. Referring toFIG. 4 , a processing unit, such as data processing unit 102 or receiver unit 104 of the analyte monitoring system 100 ofFIG. 1 , receives data related to an analyte concentration (410), which may be received from a sensor, such as sensor 101 of analyte monitoring system 100 ofFIG. 1 . The received data is analyzed and a maximum lag corrected signal is generated (420). In certain embodiments, the maximum lag corrected signal is generated by utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points. In certain embodiments, the maximum lag correction signal is generated by utilizing an aggressive lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero. The maximum lag corrected signal is analyzed to determine a corrected analyte concentration (440). - Referring still to
FIG. 4 , the received data is also analyzed and a maximum smoothing signal is generated (430) by applying a smoothing algorithm to the received data and the maximum smoothing signal is analyzed to determine the rate of change of the monitored analyte level (450). -
FIG. 5 is a flow chart illustrating certain embodiments for monitoring and processing analyte data utilizing monitored data stream. Referring toFIG. 5 , a processing unit, such as data processing unit 102 or receiver unit 104 of the analyte monitoring system 100 ofFIG. 1 , receives data related to an analyte concentration (510), which may be received from a sensor, such as sensor 101 of analyte monitoring system 100 ofFIG. 1 . The received data is sampled at a high speed to generate a monitored data stream (520). In certain embodiments, the monitored data stream is optionally generated utilizing a spline, up-sampling, or regularization algorithm. The monitored data stream is analyzed and a maximum lag corrected signal is generated (530). In certain embodiments, the maximum lag corrected signal is generated by utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points. In certain embodiments, the maximum lag correction signal is generated by utilizing an aggressive lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero. The maximum lag corrected signal is analyzed to determine a corrected analyte concentration (550). - Referring still to
FIG. 5 , the received data is also analyzed and a maximum smoothing signal is generated (540) by applying a smoothing algorithm to the received data and the maximum smoothing signal is analyzed to determine the rate of change of the monitored analyte level (560). -
FIG. 6 is a flow chart illustrating certain embodiments for monitoring and processing analyte data utilizing weighted data processing. Referring toFIG. 6 , a processing unit, such as data processing unit 102 or receiver unit 104 of the analyte monitoring system 100 ofFIG. 1 , receives data related to an analyte concentration (610), which may be received from a sensor, such as sensor 101 of analyte monitoring system 100 ofFIG. 1 . The received data is analyzed and a maximum lag corrected signal is generated (620). In certain embodiments, the maximum lag corrected signal is generated by utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points. In certain embodiments, the maximum lag correction signal is generated by utilizing an aggressive lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero. - Referring still to
FIG. 6 , the received data is also analyzed and a maximum smoothing signal is generated (630) by applying a smoothing algorithm to the received data. After determination of the maximum lag corrected signal and the maximum smoothing signal, both signals are analyzed and weighted to determine the analyte concentration (640) and rate of change of the monitored analyte level (650). In certain embodiments, the analyte concentration determination is made by weighting the maximum lag corrected signal more heavily than the maximum smoothing signal and the rate of change determination is made by weighting the maximum smoothing signal more heavily than the maximum lag corrected signal. - In certain embodiments, there is provided a method for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to the concentration of an analyte, providing one or more sets of maximum lag corrected signals from the one or more sets of monitored data stream, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical monitored data stream data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical monitored data stream, providing one or more sets of maximum smoothing signals from the set of monitored data stream, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, determining analyte concentration utilizing the one or more sets of maximum lag corrected signals, and determining a rate of change in the analyte concentration utilizing the one or more sets of maximum smoothing signals.
- In certain aspects, providing the one or more sets of maximum lag corrected signals includes utilizing an aggressive lag correction algorithm, the lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero.
- In certain aspects, monitoring a data stream including a set of contiguous source data points related to the analyte concentration includes monitoring a data stream received from a transcutaneously positioned analyte sensor, where the transcutaneously positioned analyte sensor in certain embodiments is operatively coupled to a continuous glucose monitoring system.
- In certain embodiments, one or more sets of maximum smoothing signals are further utilized to determine acceleration data of the analyte concentration.
- In accordance with another embodiment, there is provided a method for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to analyte concentration, providing one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, determining analyte concentration utilizing the one or more sets of maximum lag corrected signals, and determining a rate of change in the analyte concentration utilizing the one or more sets of maximum smoothing signals.
- In accordance with another embodiment of the present disclosure, there is provided a method for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to analyte concentration, providing one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, determining analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the one or more sets of maximum smoothing signals, wherein more weight is placed on the one or more sets of maximum lag corrected signals to determine the analyte concentration, and determining a rate of change in the analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the one or more sets of maximum smoothing signals, where more weight is placed on the one or more sets of maximum smoothing signals to determine the rate of change.
- In accordance with still another embodiment, there is provided a method for monitoring an analyte comprising monitoring a data stream including a set of contiguous source data points related to analyte concentration, providing one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, providing a first one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, providing a second one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each of the second set of maximum smoothing signals is generated utilizing a second smoothing algorithm, determining analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the first and second one or more sets of maximum smoothing signals, wherein more weight is placed on the one or more sets of maximum lag corrected signals to determine the analyte concentration, and determining a rate of change in the analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the first and second one or more sets of maximum smoothing signals, where more weight is placed on the first and second one or more sets of maximum smoothing signals to determine the rate of change.
- In certain embodiments, the first smoothing algorithm and the second smoothing algorithm are different.
- In certain embodiments, the method further includes averaging the first one or more sets of maximum smoothing signals and the second one or more sets of maximum smoothing signals.
- An apparatus in accordance with another embodiment includes one or more processors, and a memory storing instructions which, when executed by the one or more processors, causes the one or more processors to monitor a data stream including a set of contiguous source data points related to the concentration of an analyte, to provide one or more sets of monitored data stream from the set of contiguous source data points, wherein each set of monitored data stream is generated utilizing a spline, up-sampling, or regularization algorithm, to provide one or more sets of maximum lag corrected signals from the one or more sets of monitored data stream, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical monitored data stream data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical monitored data stream, to provide one or more sets of maximum smoothing signals from the set of monitored data stream, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, to determine analyte concentration utilizing the one or more sets of maximum lag corrected signals and to determine a rate of change in the analyte concentration utilizing the one or more sets of maximum smoothing signals.
- In certain embodiments, the instructions to provide the one or more sets of maximum lag corrected signals include instructions to utilize an aggressive lag correction algorithm, the lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and a pre-determined array of historical data points, to zero.
- In certain embodiments, the instructions to monitor the data stream including the set of contiguous source data points related to the analyte concentration includes instructions to monitor a data stream received from a transcutaneously positioned analyte sensor operatively coupled to the one or more processors.
- In certain embodiments, the one or more sets of maximum smoothing signals are further utilized to determine acceleration data of the analyte concentration.
- An apparatus in accordance with another embodiment includes one or more processors, and a memory storing instructions which, when executed by the one or more processors, causes the one or more processors to monitor a data stream including a set of contiguous source data points related to analyte concentration, to provide one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, to provide one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, to determine analyte concentration utilizing the one or more sets of maximum lag corrected signals and to determine a rate of change in the analyte concentration utilizing the one or more sets of maximum smoothing signals.
- An apparatus in accordance with still another embodiment includes one or more processors, and a memory storing instructions which, when executed by the one or more processors, causes the one or more processors to monitor a data stream including a set of contiguous source data points related to analyte concentration, to providing one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, to provide one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, to determine analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the one or more sets of maximum smoothing signals, wherein more weight is placed on the one or more sets of maximum lag corrected signals to determine the analyte concentration and to determine a rate of change in the analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the one or more sets of maximum smoothing signals, where more weight is placed on the one or more sets of maximum smoothing signals to determine the rate of change.
- An apparatus in accordance with still yet another embodiment includes one or more processors, and a memory storing instructions which, when executed by the one or more processors, causes the one or more processors to monitor a data stream including a set of contiguous source data points related to analyte concentration, to provide one or more sets of maximum lag corrected signals from the set of contiguous source data points, wherein each set of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points, and wherein parameters for the maximum lag correction minimize the correlation between the expected glucose error and time derivative estimates and minimize the correlation between the expected glucose error and a pre-determined array of historical source data points, to provide a first one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each set of maximum smoothing signals is generated utilizing a smoothing algorithm, to provide a second one or more sets of maximum smoothing signals from the set of contiguous source data points, wherein each of the second set of maximum smoothing signals is generated utilizing a second smoothing algorithm, to determine analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the first and second one or more sets of maximum smoothing signals, wherein more weight is placed on the one or more sets of maximum lag corrected signals to determine the analyte concentration and to determine a rate of change in the analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the first and second one or more sets of maximum smoothing signals, where more weight is placed on the first and second one or more sets of maximum smoothing signals to determine the rate of change.
- In certain embodiments, the first smoothing algorithm and the second smoothing algorithm are different.
- Certain embodiment includes instructions to average the first one or more sets of maximum smoothing signals and the second one or more sets of maximum smoothing signals.
- Various other algorithms and analysis may be applied in certain embodiments to the monitored analyte signal received from sensor 101 of analyte monitoring system 100 (
FIG. 1 ) to correct for lag and noise. Further, the weight of lag corrected and smoothed signals are varied in embodiments in order to effectively maximize noise cancellation and system accuracy. - The present disclosure contemplates modifications as would occur to those skilled in the art. For example, it is contemplated that a variety of the lag correction algorithms and the smoothing algorithms disclosed herein can be developed, altered or otherwise changed utilizing the principles provided in the present disclosure, as would occur to those skilled in the art without departing from the spirit of the present disclosure. All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference and set forth in its entirety herein.
- Further, any theory of operation, proof, or finding stated herein is meant to further enhance understanding of the present disclosure and is not intended to make the scope of the present disclosure dependent upon such theory, proof, or finding. While the disclosure has been illustrated and described in detail in the figures and foregoing description, the same is considered to be illustrative and not restrictive in character, it being understood that only certain embodiments have been shown and described and that all changes and modifications that come within the spirit of the disclosure are desired to be protected.
Claims (20)
1. A method for monitoring an analyte using an analyte monitoring system including a data processing device and a drug delivery device, comprising:
generating, using the data processing device of the analyte monitoring system, one or more first data points from a plurality of data points related to the analyte;
generating, using the data processing device of the analyte monitoring system, one or more second data points from the plurality of data points related to the analyte;
determining, using the data processing device of the analyte monitoring system, an analyte concentration based on a first weighted combination, wherein the first weighted combination comprises the one or more first data points and the one or more second data points with more weight placed on the one or more first data points than the one or more second data points; and
delivering, using the drug delivery device of the analyte monitoring system, a drug based on the determined analyte concentration.
2. The method of claim 1 , wherein generating the one or more first data points from the plurality of data points related to the analyte comprises applying a first algorithm to the plurality of data points related to the analyte, and wherein generating the one or more second data points from the plurality of data points related to the analyte comprises applying a second algorithm to the plurality of data points related to the analyte.
3. The method of claim 2 , wherein the first algorithm is a lag correction algorithm and the second algorithm is a smoothing algorithm.
4. The method of claim 1 , further comprising:
generating, using the data processing device of the analyte monitoring system, one or more third data points from the plurality of data points related to the analyte.
5. The method of claim 4 , wherein the first weighted combination comprises the one or more first data points, the one or more second data points, and the one or more third data points with more weight placed on the one or more first data points than the one or more second data points and the one or more third data points.
6. The method of claim 5 , wherein generating the one or more first data points from the plurality of data points related to the analyte comprises applying a first algorithm to the plurality of data points related to the analyte, wherein generating the one or more second data points from the plurality of data points related to the analyte comprises applying a second algorithm to the plurality of data points related to the analyte, and wherein generating the one or more third data points from the plurality of data points related to the analyte comprises applying a third algorithm to the plurality of data points related to the analyte.
7. The method of claim 6 , wherein the first algorithm is a lag correction algorithm, the second algorithm is a first smoothing algorithm, and the third algorithm is a second smoothing algorithm.
8. The method of claim 7 , wherein the first smoothing algorithm and the second smoothing algorithm are different.
9. The method of claim 1 , further comprising:
determining, using the data processing device of the analyte monitoring system, a rate of change in the analyte concentration based on a second weighted combination, wherein the second weighted combination comprises the one or more first data points and the one or more second data points with more weight placed on the one or more second data points than the one or more first data points.
10. The method of claim 1 , further comprising averaging the one or more first data points and the one or more second data points.
11. The method of claim 1 , further comprising:
receiving the plurality of data points related to the analyte from an analyte sensor.
12. The method of claim 11 , wherein the analyte sensor includes a plurality of electrodes including a working electrode comprising an analyte-responsive enzyme.
13. The method of claim 12 , wherein the enzyme is bound to a polymer disposed on the working electrode.
14. The method of claim 12 , wherein the working electrode comprises a mediator.
15. The method of claim 14 , wherein the mediator is bound to a polymer disposed on the working electrode.
16. The method of claim 14 , wherein the mediator is crosslinked with a polymer disposed on the working electrode.
17. The method of claim 11 , wherein the analyte sensor includes a plurality of electrodes including a working electrode comprising a mediator.
18. The method of claim 17 , wherein the mediator is bound to a polymer disposed on the working electrode, or wherein the mediator is crosslinked with the polymer disposed on the working electrode.
19. A system, comprising:
an analyte sensor configured to generate a plurality of data points related to a concentration of an analyte;
a data processing device operatively coupled to the analyte sensor, wherein the data processing device is configured to:
generate one or more first data points from the plurality of data points related to the analyte;
generate one or more second data points from the plurality of data points related to the analyte; and
determine an analyte concentration based on a weighted combination, wherein the weighted combination comprises the one or more first data points and the one or more second data points with more weight placed on the one or more first data points than the one or more second data point; and
a drug delivery device configured to deliver a drug based on the determined analyte concentration.
20. A method for monitoring an analyte using an analyte monitoring system including a data processing device and a drug delivery device, comprising:
generating, using the data processing device of the analyte monitoring system, one or more first data points from a plurality of data points related to the analyte;
generating, using the data processing device of the analyte monitoring system, one or more second data points from the plurality of data points related to the analyte;
determining, using the data processing device of the analyte monitoring system, a rate of change in an analyte concentration based on a weighted combination, wherein the weighted combination comprises the one or more first data points and the one or more second data points with more weight placed on the one or more first data points than the one or more second data points; and
delivering, using the drug delivery device of the analyte monitoring system, a drug based on the determined rate of change in the analyte concentration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/868,386 US20230007916A1 (en) | 2011-11-25 | 2022-07-19 | Analyte monitoring system and methods of use |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161563743P | 2011-11-25 | 2011-11-25 | |
US13/683,996 US9339217B2 (en) | 2011-11-25 | 2012-11-21 | Analyte monitoring system and methods of use |
US15/143,413 US10082493B2 (en) | 2011-11-25 | 2016-04-29 | Analyte monitoring system and methods of use |
US16/111,099 US11391723B2 (en) | 2011-11-25 | 2018-08-23 | Analyte monitoring system and methods of use |
US17/868,386 US20230007916A1 (en) | 2011-11-25 | 2022-07-19 | Analyte monitoring system and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/111,099 Continuation US11391723B2 (en) | 2011-11-25 | 2018-08-23 | Analyte monitoring system and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230007916A1 true US20230007916A1 (en) | 2023-01-12 |
Family
ID=48467468
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/683,996 Expired - Fee Related US9339217B2 (en) | 2006-03-31 | 2012-11-21 | Analyte monitoring system and methods of use |
US15/143,413 Active US10082493B2 (en) | 2011-11-25 | 2016-04-29 | Analyte monitoring system and methods of use |
US16/111,099 Active 2033-10-25 US11391723B2 (en) | 2011-11-25 | 2018-08-23 | Analyte monitoring system and methods of use |
US17/868,386 Pending US20230007916A1 (en) | 2011-11-25 | 2022-07-19 | Analyte monitoring system and methods of use |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/683,996 Expired - Fee Related US9339217B2 (en) | 2006-03-31 | 2012-11-21 | Analyte monitoring system and methods of use |
US15/143,413 Active US10082493B2 (en) | 2011-11-25 | 2016-04-29 | Analyte monitoring system and methods of use |
US16/111,099 Active 2033-10-25 US11391723B2 (en) | 2011-11-25 | 2018-08-23 | Analyte monitoring system and methods of use |
Country Status (2)
Country | Link |
---|---|
US (4) | US9339217B2 (en) |
WO (1) | WO2013078426A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US20080199894A1 (en) | 2007-02-15 | 2008-08-21 | Abbott Diabetes Care, Inc. | Device and method for automatic data acquisition and/or detection |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
DK3988470T3 (en) | 2009-08-31 | 2023-08-28 | Abbott Diabetes Care Inc | Display devices for a medical device |
US8185181B2 (en) | 2009-10-30 | 2012-05-22 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
DK3575796T3 (en) | 2011-04-15 | 2021-01-18 | Dexcom Inc | ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION |
US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
EP2890297B1 (en) | 2012-08-30 | 2018-04-11 | Abbott Diabetes Care, Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
EP2901153A4 (en) | 2012-09-26 | 2016-04-27 | Abbott Diabetes Care Inc | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
WO2017040927A1 (en) * | 2015-09-02 | 2017-03-09 | University Of Virginia Patent Foundation | System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users |
AU2018354120A1 (en) | 2017-10-24 | 2020-04-23 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
Family Cites Families (708)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1191363A (en) | 1968-02-19 | 1970-05-13 | Pavelle Ltd | Improvements in or relating to Electronic Thermostats. |
US3949388A (en) | 1972-11-13 | 1976-04-06 | Monitron Industries, Inc. | Physiological sensor and transmitter |
US3926760A (en) | 1973-09-28 | 1975-12-16 | Du Pont | Process for electrophoretic deposition of polymer |
US4245634A (en) | 1975-01-22 | 1981-01-20 | Hospital For Sick Children | Artificial beta cell |
US4036749A (en) | 1975-04-30 | 1977-07-19 | Anderson Donald R | Purification of saline water |
US3960497A (en) | 1975-08-19 | 1976-06-01 | Beckman Instruments, Inc. | Chemical analyzer with automatic calibration |
US4033330A (en) | 1975-09-08 | 1977-07-05 | Hewlett-Packard Company | Transcutaneous pH measuring instrument |
US4055175A (en) | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
US4129128A (en) | 1977-02-23 | 1978-12-12 | Mcfarlane Richard H | Securing device for catheter placement assembly |
US4344438A (en) | 1978-08-02 | 1982-08-17 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Optical sensor of plasma constituents |
AU530979B2 (en) | 1978-12-07 | 1983-08-04 | Aus. Training Aids Pty. Ltd., | Detecting position of bullet fired at target |
US4373527B1 (en) | 1979-04-27 | 1995-06-27 | Univ Johns Hopkins | Implantable programmable medication infusion system |
CS210174B1 (en) | 1979-07-12 | 1982-01-29 | Ivan Emmer | Method of making the electric hygrometric sensor |
US4425920A (en) | 1980-10-24 | 1984-01-17 | Purdue Research Foundation | Apparatus and method for measurement and control of blood pressure |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4392849A (en) | 1981-07-27 | 1983-07-12 | The Cleveland Clinic Foundation | Infusion pump controller |
DE3138194A1 (en) | 1981-09-25 | 1983-04-14 | Basf Ag, 6700 Ludwigshafen | WATER-INSOLUBLE POROESES PROTEIN MATERIAL, THEIR PRODUCTION AND USE |
US4494950A (en) | 1982-01-19 | 1985-01-22 | The Johns Hopkins University | Plural module medication delivery system |
US4462048A (en) | 1982-02-11 | 1984-07-24 | Rca Corporation | Noise reduction circuitry for audio signals |
FI831399L (en) | 1982-04-29 | 1983-10-30 | Agripat Sa | KONTAKTLINS AV HAERDAD POLYVINYL ALCOHOL |
EP0098592A3 (en) | 1982-07-06 | 1985-08-21 | Fujisawa Pharmaceutical Co., Ltd. | Portable artificial pancreas |
US4509531A (en) | 1982-07-28 | 1985-04-09 | Teledyne Industries, Inc. | Personal physiological monitor |
US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
US4527240A (en) | 1982-12-29 | 1985-07-02 | Kvitash Vadim I | Balascopy method for detecting and rapidly evaluating multiple imbalances within multi-parametric systems |
US5509410A (en) | 1983-06-06 | 1996-04-23 | Medisense, Inc. | Strip electrode including screen printing of a single layer |
CA1226036A (en) | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
US4538616A (en) | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
DE3429596A1 (en) | 1984-08-10 | 1986-02-20 | Siemens AG, 1000 Berlin und 8000 München | DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE |
CA1254091A (en) | 1984-09-28 | 1989-05-16 | Vladimir Feingold | Implantable medication infusion system |
US4847785A (en) | 1985-01-22 | 1989-07-11 | International Business Machines Corp. | Interactive display for trend or bar graph |
US5279294A (en) | 1985-04-08 | 1994-01-18 | Cascade Medical, Inc. | Medical diagnostic system |
US4671288A (en) | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4890620A (en) | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
US4757022A (en) | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
US4731726A (en) | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
US5055171A (en) | 1986-10-06 | 1991-10-08 | T And G Corporation | Ionic semiconductor materials and applications thereof |
US4854322A (en) | 1987-02-25 | 1989-08-08 | Ash Medical Systems, Inc. | Capillary filtration and collection device for long-term monitoring of blood constituents |
US5002054A (en) | 1987-02-25 | 1991-03-26 | Ash Medical Systems, Inc. | Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body |
US4777953A (en) | 1987-02-25 | 1988-10-18 | Ash Medical Systems, Inc. | Capillary filtration and collection method for long-term monitoring of blood constituents |
US4759828A (en) | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US4749985A (en) | 1987-04-13 | 1988-06-07 | United States Of America As Represented By The United States Department Of Energy | Functional relationship-based alarm processing |
EP0290683A3 (en) | 1987-05-01 | 1988-12-14 | Diva Medical Systems B.V. | Diabetes management system and apparatus |
GB8725936D0 (en) | 1987-11-05 | 1987-12-09 | Genetics Int Inc | Sensing system |
US4925268A (en) | 1988-07-25 | 1990-05-15 | Abbott Laboratories | Fiber-optic physiological probes |
EP0353328A1 (en) | 1988-08-03 | 1990-02-07 | Dräger Nederland B.V. | A polarographic-amperometric three-electrode sensor |
US5340722A (en) | 1988-08-24 | 1994-08-23 | Avl Medical Instruments Ag | Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method |
US5108889A (en) | 1988-10-12 | 1992-04-28 | Thorne, Smith, Astill Technologies, Inc. | Assay for determining analyte using mercury release followed by detection via interaction with aluminum |
US5360404A (en) | 1988-12-14 | 1994-11-01 | Inviro Medical Devices Ltd. | Needle guard and needle assembly for syringe |
US5077476A (en) | 1990-06-27 | 1991-12-31 | Futrex, Inc. | Instrument for non-invasive measurement of blood glucose |
US5068536A (en) | 1989-01-19 | 1991-11-26 | Futrex, Inc. | Method for providing custom calibration for near infrared instruments for measurement of blood glucose |
DK0385805T3 (en) | 1989-03-03 | 1996-09-23 | Edward W Stark | Method and apparatus for signal processing |
JPH02298855A (en) | 1989-03-20 | 1990-12-11 | Assoc Univ Inc | Electrochemical biosensor using immobilized enzyme and redox polymer |
US4953552A (en) | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
EP0396788A1 (en) | 1989-05-08 | 1990-11-14 | Dräger Nederland B.V. | Process and sensor for measuring the glucose content of glucosecontaining fluids |
FR2648353B1 (en) | 1989-06-16 | 1992-03-27 | Europhor Sa | MICRODIALYSIS PROBE |
US5431160A (en) | 1989-07-19 | 1995-07-11 | University Of New Mexico | Miniature implantable refillable glucose sensor and material therefor |
US4986271A (en) | 1989-07-19 | 1991-01-22 | The University Of New Mexico | Vivo refillable glucose sensor |
US5320725A (en) | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5264105A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
US5568400A (en) | 1989-09-01 | 1996-10-22 | Stark; Edward W. | Multiplicative signal correction method and apparatus |
US5050612A (en) | 1989-09-12 | 1991-09-24 | Matsumura Kenneth N | Device for computer-assisted monitoring of the body |
US5082550A (en) | 1989-12-11 | 1992-01-21 | The United States Of America As Represented By The Department Of Energy | Enzyme electrochemical sensor electrode and method of making it |
US5342789A (en) | 1989-12-14 | 1994-08-30 | Sensor Technologies, Inc. | Method and device for detecting and quantifying glucose in body fluids |
US5051688A (en) | 1989-12-20 | 1991-09-24 | Rohm Co., Ltd. | Crossed coil meter driving device having a plurality of input parameters |
US5165407A (en) | 1990-04-19 | 1992-11-24 | The University Of Kansas | Implantable glucose sensor |
GB2243211A (en) | 1990-04-20 | 1991-10-23 | Philips Electronic Associated | Analytical instrument and method of calibrating an analytical instrument |
US5202261A (en) | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
JP2701977B2 (en) | 1990-09-28 | 1998-01-21 | ファイザー インク | Dosage form containing hydrophobic medium |
US5251126A (en) | 1990-10-29 | 1993-10-05 | Miles Inc. | Diabetes data analysis and interpretation method |
DE69126885T3 (en) | 1990-12-12 | 2001-10-18 | Sherwood Serv Ag | CALIBRATION OF AN INFRARED THERMOMETER BY MEANS OF AREA CALIBRATION DISPLAY |
US5228449A (en) | 1991-01-22 | 1993-07-20 | Athanasios G. Christ | System and method for detecting out-of-hospital cardiac emergencies and summoning emergency assistance |
US5262305A (en) | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
CA2050057A1 (en) | 1991-03-04 | 1992-09-05 | Adam Heller | Interferant eliminating biosensors |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5632272A (en) | 1991-03-07 | 1997-05-27 | Masimo Corporation | Signal processing apparatus |
US5469855A (en) | 1991-03-08 | 1995-11-28 | Exergen Corporation | Continuous temperature monitor |
US5135004A (en) | 1991-03-12 | 1992-08-04 | Incontrol, Inc. | Implantable myocardial ischemia monitor and related method |
US5204264A (en) | 1991-03-14 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method for validation of calibration standards in an automatic chemical analyzer |
US5122925A (en) | 1991-04-22 | 1992-06-16 | Control Products, Inc. | Package for electronic components |
US5328460A (en) | 1991-06-21 | 1994-07-12 | Pacesetter Infusion, Ltd. | Implantable medication infusion pump including self-contained acoustic fault detection apparatus |
US5231988A (en) | 1991-08-09 | 1993-08-03 | Cyberonics, Inc. | Treatment of endocrine disorders by nerve stimulation |
GB9120144D0 (en) | 1991-09-20 | 1991-11-06 | Imperial College | A dialysis electrode device |
US5322063A (en) | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
US5372427A (en) | 1991-12-19 | 1994-12-13 | Texas Instruments Incorporated | Temperature sensor |
US5285792A (en) | 1992-01-10 | 1994-02-15 | Physio-Control Corporation | System for producing prioritized alarm messages in a medical instrument |
US5246867A (en) | 1992-01-17 | 1993-09-21 | University Of Maryland At Baltimore | Determination and quantification of saccharides by luminescence lifetimes and energy transfer |
IL104365A0 (en) | 1992-01-31 | 1993-05-13 | Gensia Pharma | Method and apparatus for closed loop drug delivery |
US5328927A (en) | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
FR2690622B1 (en) | 1992-04-29 | 1995-01-20 | Chronotec | Programmable ambulatory infusion pump system. |
US5711001A (en) | 1992-05-08 | 1998-01-20 | Motorola, Inc. | Method and circuit for acquisition by a radio receiver |
GB9211402D0 (en) | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
DK95792A (en) | 1992-07-24 | 1994-01-25 | Radiometer As | Sensor for non-invasive, in vivo determination of an analyte and blood flow |
US6283761B1 (en) | 1992-09-08 | 2001-09-04 | Raymond Anthony Joao | Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information |
WO1994010553A1 (en) | 1992-10-23 | 1994-05-11 | Optex Biomedical, Inc. | Fibre-optic probe for the measurement of fluid parameters |
US5899855A (en) | 1992-11-17 | 1999-05-04 | Health Hero Network, Inc. | Modular microprocessor-based health monitoring system |
US5601435A (en) | 1994-11-04 | 1997-02-11 | Intercare | Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information |
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
ZA938555B (en) | 1992-11-23 | 1994-08-02 | Lilly Co Eli | Technique to improve the performance of electrochemical sensors |
US5410326A (en) | 1992-12-04 | 1995-04-25 | Goldstein; Steven W. | Programmable remote control device for interacting with a plurality of remotely controlled devices |
US5299571A (en) | 1993-01-22 | 1994-04-05 | Eli Lilly And Company | Apparatus and method for implantation of sensors |
DK0622119T3 (en) | 1993-04-23 | 2000-04-10 | Roche Diagnostics Gmbh | Test element storage system |
US5384547A (en) | 1993-08-02 | 1995-01-24 | Motorola, Inc. | Apparatus and method for attenuating a multicarrier input signal of a linear device |
DE4329898A1 (en) | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
US5438983A (en) | 1993-09-13 | 1995-08-08 | Hewlett-Packard Company | Patient alarm detection using trend vector analysis |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
US5497772A (en) | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
DE4401400A1 (en) | 1994-01-19 | 1995-07-20 | Ernst Prof Dr Pfeiffer | Method and arrangement for continuously monitoring the concentration of a metabolite |
US5536249A (en) | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
US5391250A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5390671A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
WO1995027272A1 (en) | 1994-04-04 | 1995-10-12 | Motorola Inc. | Method and apparatus for activating and accessing remote meter interface devices |
US5609575A (en) | 1994-04-11 | 1997-03-11 | Graseby Medical Limited | Infusion pump and method with dose-rate calculation |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
US5472317A (en) | 1994-06-03 | 1995-12-05 | Minimed Inc. | Mounting clip for a medication infusion pump |
US5919141A (en) | 1994-11-15 | 1999-07-06 | Life Sensing Instrument Company, Inc. | Vital sign remote monitoring device |
US5568806A (en) | 1995-02-16 | 1996-10-29 | Minimed Inc. | Transcutaneous sensor insertion set |
US5586553A (en) | 1995-02-16 | 1996-12-24 | Minimed Inc. | Transcutaneous sensor insertion set |
US5564434A (en) | 1995-02-27 | 1996-10-15 | Medtronic, Inc. | Implantable capacitive absolute pressure and temperature sensor |
US5752512A (en) | 1995-05-10 | 1998-05-19 | Massachusetts Institute Of Technology | Apparatus and method for non-invasive blood analyte measurement |
US5628310A (en) | 1995-05-19 | 1997-05-13 | Joseph R. Lakowicz | Method and apparatus to perform trans-cutaneous analyte monitoring |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US5555190A (en) | 1995-07-12 | 1996-09-10 | Micro Motion, Inc. | Method and apparatus for adaptive line enhancement in Coriolis mass flow meter measurement |
US7016713B2 (en) | 1995-08-09 | 2006-03-21 | Inlight Solutions, Inc. | Non-invasive determination of direction and rate of change of an analyte |
US5665222A (en) | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
US5972199A (en) | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
US5748103A (en) | 1995-11-13 | 1998-05-05 | Vitalcom, Inc. | Two-way TDMA telemetry system with power conservation features |
US5711861A (en) | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
FI960636A (en) | 1996-02-12 | 1997-08-13 | Nokia Mobile Phones Ltd | A procedure for monitoring the health of a patient |
DE19618597B4 (en) | 1996-05-09 | 2005-07-21 | Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm | Method for determining the concentration of tissue glucose |
US5735285A (en) | 1996-06-04 | 1998-04-07 | Data Critical Corp. | Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals |
EP0914178B1 (en) | 1996-06-18 | 2003-03-12 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
JP3581218B2 (en) | 1996-07-03 | 2004-10-27 | 株式会社東芝 | Mobile communication terminal device and its mobile phone and data terminal device |
EP0923335B1 (en) | 1996-07-08 | 2006-08-23 | Animas Corporation | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
US6027459A (en) | 1996-12-06 | 2000-02-22 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
US5964993A (en) | 1996-12-19 | 1999-10-12 | Implanted Biosystems Inc. | Glucose sensor |
US5914026A (en) | 1997-01-06 | 1999-06-22 | Implanted Biosystems Inc. | Implantable sensor employing an auxiliary electrode |
US6032119A (en) | 1997-01-16 | 2000-02-29 | Health Hero Network, Inc. | Personalized display of health information |
US6122351A (en) | 1997-01-21 | 2000-09-19 | Med Graph, Inc. | Method and system aiding medical diagnosis and treatment |
US6093172A (en) | 1997-02-05 | 2000-07-25 | Minimed Inc. | Injector for a subcutaneous insertion set |
US6607509B2 (en) | 1997-12-31 | 2003-08-19 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
JP3394262B2 (en) | 1997-02-06 | 2003-04-07 | セラセンス、インク. | Small volume in vitro analyte sensor |
EP1011426A1 (en) | 1997-02-26 | 2000-06-28 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
US6159147A (en) | 1997-02-28 | 2000-12-12 | Qrs Diagnostics, Llc | Personal computer card for collection of real-time biological data |
US6558321B1 (en) | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US6699187B2 (en) | 1997-03-27 | 2004-03-02 | Medtronic, Inc. | System and method for providing remote expert communications and video capabilities for use during a medical procedure |
US6270455B1 (en) | 1997-03-28 | 2001-08-07 | Health Hero Network, Inc. | Networked system for interactive communications and remote monitoring of drug delivery |
US5961451A (en) | 1997-04-07 | 1999-10-05 | Motorola, Inc. | Noninvasive apparatus having a retaining member to retain a removable biosensor |
US5942979A (en) | 1997-04-07 | 1999-08-24 | Luppino; Richard | On guard vehicle safety warning system |
US5935224A (en) | 1997-04-24 | 1999-08-10 | Microsoft Corporation | Method and apparatus for adaptively coupling an external peripheral device to either a universal serial bus port on a computer or hub or a game port on a computer |
US7267665B2 (en) | 1999-06-03 | 2007-09-11 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US5954643A (en) | 1997-06-09 | 1999-09-21 | Minimid Inc. | Insertion set for a transcutaneous sensor |
US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
CA2294610A1 (en) | 1997-06-16 | 1998-12-23 | George Moshe Katz | Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods |
US6066243A (en) | 1997-07-22 | 2000-05-23 | Diametrics Medical, Inc. | Portable immediate response medical analyzer having multiple testing modules |
US6259937B1 (en) | 1997-09-12 | 2001-07-10 | Alfred E. Mann Foundation | Implantable substrate sensor |
DE19836401A1 (en) | 1997-09-19 | 2000-02-17 | Salcomp Oy Salo | Device for charging accumulators |
US6117290A (en) | 1997-09-26 | 2000-09-12 | Pepex Biomedical, Llc | System and method for measuring a bioanalyte such as lactate |
US5904671A (en) | 1997-10-03 | 1999-05-18 | Navot; Nir | Tampon wetness detection system |
US6119028A (en) | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
US6088608A (en) | 1997-10-20 | 2000-07-11 | Alfred E. Mann Foundation | Electrochemical sensor and integrity tests therefor |
FI107080B (en) | 1997-10-27 | 2001-05-31 | Nokia Mobile Phones Ltd | measuring device |
ES2281143T3 (en) | 1997-11-12 | 2007-09-16 | Lightouch Medical, Inc. | METHOD FOR THE NON-INVASIVE MEASUREMENT OF AN ANALYTE. |
US7401111B1 (en) | 1997-12-04 | 2008-07-15 | Roche Diagnostic Operations, Inc. | Instrument setup utility program |
NZ504879A (en) | 1997-12-04 | 2003-05-30 | Roche Diagnostics Corp | Instrument for engaging a power cell |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
CA2575064C (en) | 1997-12-31 | 2010-02-02 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6103033A (en) | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
US6024699A (en) | 1998-03-13 | 2000-02-15 | Healthware Corporation | Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients |
JPH11296598A (en) | 1998-04-07 | 1999-10-29 | Seizaburo Arita | System and method for predicting blood-sugar level and record medium where same method is recorded |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
JP2002514452A (en) | 1998-05-13 | 2002-05-21 | シグナス, インコーポレイテッド | Signal processing for measurement of physiological analytes |
PT1077634E (en) | 1998-05-13 | 2003-12-31 | Cygnus Therapeutic Systems | MONITORING OF PHYSIOLOGICAL SUBSTANCES TO BE ANALYZED |
US7043287B1 (en) | 1998-05-18 | 2006-05-09 | Abbott Laboratories | Method for modulating light penetration depth in tissue and diagnostic applications using same |
US6121611A (en) | 1998-05-20 | 2000-09-19 | Molecular Imaging Corporation | Force sensing probe for scanning probe microscopy |
US6223283B1 (en) | 1998-07-17 | 2001-04-24 | Compaq Computer Corporation | Method and apparatus for identifying display monitor functionality and compatibility |
US6493069B1 (en) | 1998-07-24 | 2002-12-10 | Terumo Kabushiki Kaisha | Method and instrument for measuring blood sugar level |
US6248067B1 (en) | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6480753B1 (en) | 1998-09-04 | 2002-11-12 | Ncr Corporation | Communications, particularly in the domestic environment |
KR20000019716A (en) | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising bioflavonoid compounds for descending blood sugar |
US6740518B1 (en) | 1998-09-17 | 2004-05-25 | Clinical Micro Sensors, Inc. | Signal detection techniques for the detection of analytes |
US6254586B1 (en) | 1998-09-25 | 2001-07-03 | Minimed Inc. | Method and kit for supplying a fluid to a subcutaneous placement site |
JP3537136B2 (en) | 1998-09-30 | 2004-06-14 | シグナス, インコーポレイテッド | Method and apparatus for predicting physiological values |
US6402689B1 (en) | 1998-09-30 | 2002-06-11 | Sicel Technologies, Inc. | Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
DK1413245T3 (en) | 1998-10-08 | 2011-10-10 | Medtronic Minimed Inc | Installations for monitoring a characteristic of remote sensing |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
JP2002528211A (en) | 1998-11-03 | 2002-09-03 | ハリー ルイス プラット | Portable physiological signal acquisition device |
US6602469B1 (en) | 1998-11-09 | 2003-08-05 | Lifestream Technologies, Inc. | Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system |
EP1131114B1 (en) | 1998-11-20 | 2004-06-16 | The University of Connecticut | Apparatus and method for control of tissue/implant interactions |
US7436511B2 (en) | 1999-01-22 | 2008-10-14 | Sensys Medical, Inc. | Analyte filter method and apparatus |
US6561978B1 (en) | 1999-02-12 | 2003-05-13 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
US6314317B1 (en) | 1999-02-18 | 2001-11-06 | Biovalve Technologies, Inc. | Electroactive pore |
US6360888B1 (en) | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
US6424847B1 (en) | 1999-02-25 | 2002-07-23 | Medtronic Minimed, Inc. | Glucose monitor calibration methods |
GB9907815D0 (en) | 1999-04-06 | 1999-06-02 | Univ Cambridge Tech | Implantable sensor |
US6285897B1 (en) | 1999-04-07 | 2001-09-04 | Endonetics, Inc. | Remote physiological monitoring system |
US6200265B1 (en) | 1999-04-16 | 2001-03-13 | Medtronic, Inc. | Peripheral memory patch and access method for use with an implantable medical device |
US6669663B1 (en) | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
US6359444B1 (en) | 1999-05-28 | 2002-03-19 | University Of Kentucky Research Foundation | Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing |
US6546268B1 (en) | 1999-06-02 | 2003-04-08 | Ball Semiconductor, Inc. | Glucose sensor |
US7806886B2 (en) | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
DE19925910B4 (en) | 1999-06-07 | 2005-04-28 | Siemens Ag | Method for processing or processing data |
JP2003505754A (en) | 1999-06-10 | 2003-02-12 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method of identifying valid signal in measurement signal |
US6423035B1 (en) | 1999-06-18 | 2002-07-23 | Animas Corporation | Infusion pump with a sealed drive mechanism and improved method of occlusion detection |
EP2322645A1 (en) | 1999-06-18 | 2011-05-18 | Abbott Diabetes Care Inc. | Mass transport limited in vivo analyte sensor |
US6471689B1 (en) | 1999-08-16 | 2002-10-29 | Thomas Jefferson University | Implantable drug delivery catheter system with capillary interface |
US6923763B1 (en) | 1999-08-23 | 2005-08-02 | University Of Virginia Patent Foundation | Method and apparatus for predicting the risk of hypoglycemia |
US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
US6343225B1 (en) | 1999-09-14 | 2002-01-29 | Implanted Biosystems, Inc. | Implantable glucose sensor |
AT408182B (en) | 1999-09-17 | 2001-09-25 | Schaupp Lukas Dipl Ing Dr Tech | DEVICE FOR VIVO MEASURING SIZES IN LIVING ORGANISMS |
EP1217942A1 (en) | 1999-09-24 | 2002-07-03 | Healthetech, Inc. | Physiological monitor and associated computation, display and communication unit |
US6478736B1 (en) | 1999-10-08 | 2002-11-12 | Healthetech, Inc. | Integrated calorie management system |
US7317938B2 (en) | 1999-10-08 | 2008-01-08 | Sensys Medical, Inc. | Method of adapting in-vitro models to aid in noninvasive glucose determination |
US20060091006A1 (en) | 1999-11-04 | 2006-05-04 | Yi Wang | Analyte sensor with insertion monitor, and methods |
US6616819B1 (en) | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
WO2001036660A2 (en) | 1999-11-15 | 2001-05-25 | Therasense, Inc. | Transition metal complexes attached to a polymer via a flexible chain |
US6658396B1 (en) | 1999-11-29 | 2003-12-02 | Tang Sharon S | Neural network drug dosage estimation |
US7286894B1 (en) | 2000-01-07 | 2007-10-23 | Pasco Scientific | Hand-held computer device and method for interactive data acquisition, analysis, annotation, and calibration |
JP3449958B2 (en) | 2000-01-18 | 2003-09-22 | 理想科学工業株式会社 | Printing system, printing method, and computer-readable recording medium storing printing program |
US7369635B2 (en) | 2000-01-21 | 2008-05-06 | Medtronic Minimed, Inc. | Rapid discrimination preambles and methods for using the same |
US6873268B2 (en) | 2000-01-21 | 2005-03-29 | Medtronic Minimed, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
JP4703083B2 (en) | 2000-01-21 | 2011-06-15 | メドトロニック ミニメド インコーポレイテッド | Medical system |
CA2396749C (en) | 2000-01-21 | 2011-07-19 | Medical Research Group, Inc. | Ambulatory medical apparatus and method having telemetry modifiable control software |
US7003336B2 (en) | 2000-02-10 | 2006-02-21 | Medtronic Minimed, Inc. | Analyte sensor method of making the same |
US20030060765A1 (en) | 2000-02-16 | 2003-03-27 | Arthur Campbell | Infusion device menu structure and method of using the same |
US7890295B2 (en) | 2000-02-23 | 2011-02-15 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US7027931B1 (en) | 2000-02-24 | 2006-04-11 | Bionostics, Inc. | System for statistical analysis of quality control data |
WO2001072208A2 (en) | 2000-03-29 | 2001-10-04 | University Of Virginia Patent Foundation | Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data |
US6610012B2 (en) | 2000-04-10 | 2003-08-26 | Healthetech, Inc. | System and method for remote pregnancy monitoring |
US6440068B1 (en) | 2000-04-28 | 2002-08-27 | International Business Machines Corporation | Measuring user health as measured by multiple diverse health measurement devices utilizing a personal storage device |
WO2001088524A1 (en) | 2000-05-12 | 2001-11-22 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
US7769420B2 (en) | 2000-05-15 | 2010-08-03 | Silver James H | Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
WO2001088534A2 (en) | 2000-05-16 | 2001-11-22 | Cygnus, Inc. | Methods for improving performance and reliability of biosensors |
EP1304856A4 (en) | 2000-05-31 | 2006-07-19 | Arkray Inc | Remote data control system and measuring data gathering method |
EP1309271B1 (en) | 2000-08-18 | 2008-04-16 | Animas Technologies LLC | Device for prediction of hypoglycemic events |
US6633772B2 (en) | 2000-08-18 | 2003-10-14 | Cygnus, Inc. | Formulation and manipulation of databases of analyte and associated values |
AU2001288292A1 (en) | 2000-08-21 | 2002-03-04 | Euroceltique S.A. | Near infrared blood glucose monitoring system |
US6572545B2 (en) | 2000-09-22 | 2003-06-03 | Knobbe, Lim & Buckingham | Method and apparatus for real-time control of physiological parameters |
ATE314822T1 (en) | 2000-10-10 | 2006-02-15 | Microchips Inc | MICROCHIP RESERVOIR DEVICES WITH WIRELESS TRANSMISSION OF ENERGY AND DATA |
US6695860B1 (en) | 2000-11-13 | 2004-02-24 | Isense Corp. | Transcutaneous sensor insertion device |
US7052483B2 (en) | 2000-12-19 | 2006-05-30 | Animas Corporation | Transcutaneous inserter for low-profile infusion sets |
US20020147135A1 (en) | 2000-12-21 | 2002-10-10 | Oliver Schnell | Method and device for producing an adapted travel treatment plan for administering a medicine in the event of a long-haul journey |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6666821B2 (en) | 2001-01-08 | 2003-12-23 | Medtronic, Inc. | Sensor system |
US6970529B2 (en) | 2001-01-16 | 2005-11-29 | International Business Machines Corporation | Unified digital architecture |
US6529752B2 (en) | 2001-01-17 | 2003-03-04 | David T. Krausman | Sleep disorder breathing event counter |
US20040197846A1 (en) | 2001-01-18 | 2004-10-07 | Linda Hockersmith | Determination of glucose sensitivity and a method to manipulate blood glucose concentration |
CN1525834A (en) | 2001-01-22 | 2004-09-01 | - | Lancet device having capillary action |
US6525330B2 (en) | 2001-02-28 | 2003-02-25 | Home Diagnostics, Inc. | Method of strip insertion detection |
US20030023461A1 (en) | 2001-03-14 | 2003-01-30 | Dan Quintanilla | Internet based therapy management system |
CA2441054A1 (en) | 2001-03-14 | 2002-09-19 | Milton E. Hamilton | Tracking device |
US6968294B2 (en) | 2001-03-15 | 2005-11-22 | Koninklijke Philips Electronics N.V. | Automatic system for monitoring person requiring care and his/her caretaker |
WO2002078512A2 (en) | 2001-04-02 | 2002-10-10 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6574490B2 (en) | 2001-04-11 | 2003-06-03 | Rio Grande Medical Technologies, Inc. | System for non-invasive measurement of glucose in humans |
US6983176B2 (en) | 2001-04-11 | 2006-01-03 | Rio Grande Medical Technologies, Inc. | Optically similar reference samples and related methods for multivariate calibration models used in optical spectroscopy |
GR1003802B (en) | 2001-04-17 | 2002-02-08 | Micrel �.�.�. ������� ��������� ��������������� ��������� | Tele-medicine system |
US6698269B2 (en) | 2001-04-27 | 2004-03-02 | Oceana Sensor Technologies, Inc. | Transducer in-situ testing apparatus and method |
US7395214B2 (en) | 2001-05-11 | 2008-07-01 | Craig P Shillingburg | Apparatus, device and method for prescribing, administering and monitoring a treatment regimen for a patient |
US6676816B2 (en) | 2001-05-11 | 2004-01-13 | Therasense, Inc. | Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes |
US6932894B2 (en) | 2001-05-15 | 2005-08-23 | Therasense, Inc. | Biosensor membranes composed of polymers containing heterocyclic nitrogens |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US7179226B2 (en) | 2001-06-21 | 2007-02-20 | Animas Corporation | System and method for managing diabetes |
ATE520341T1 (en) | 2001-06-22 | 2011-09-15 | Nellcor Puritan Bennett Ie | WAVELET-BASED ANALYSIS OF PULSE OXIMETRY SIGNALS |
US7011630B2 (en) | 2001-06-22 | 2006-03-14 | Animas Technologies, Llc | Methods for computing rolling analyte measurement values, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods |
US7044911B2 (en) | 2001-06-29 | 2006-05-16 | Philometron, Inc. | Gateway platform for biological monitoring and delivery of therapeutic compounds |
US20030208113A1 (en) | 2001-07-18 | 2003-11-06 | Mault James R | Closed loop glycemic index system |
US6754516B2 (en) | 2001-07-19 | 2004-06-22 | Nellcor Puritan Bennett Incorporated | Nuisance alarm reductions in a physiological monitor |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
US6788965B2 (en) | 2001-08-03 | 2004-09-07 | Sensys Medical, Inc. | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes |
EP1421381A1 (en) | 2001-08-03 | 2004-05-26 | The General Hospital Corporation | System, process and diagnostic arrangement establishing and monitoring medication doses for patients |
JP3775263B2 (en) | 2001-08-10 | 2006-05-17 | ニプロ株式会社 | Recording medium and blood glucose measurement system using the recording medium |
JP2004538078A (en) | 2001-08-20 | 2004-12-24 | インバネス・メディカル・リミテッド | Wireless diabetes management device and method of using wireless diabetes management device |
CA2458195C (en) | 2001-08-22 | 2009-11-03 | Instrumentation Laboratory Company | Method and apparatus for calibrating electrochemical sensors |
JP3962250B2 (en) | 2001-08-29 | 2007-08-22 | 株式会社レアメタル | In vivo information detection system and tag device and relay device used therefor |
US6740072B2 (en) | 2001-09-07 | 2004-05-25 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
US6827702B2 (en) | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
US7052591B2 (en) | 2001-09-21 | 2006-05-30 | Therasense, Inc. | Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking |
US6830562B2 (en) | 2001-09-27 | 2004-12-14 | Unomedical A/S | Injector device for placing a subcutaneous infusion set |
US20050137480A1 (en) | 2001-10-01 | 2005-06-23 | Eckhard Alt | Remote control of implantable device through medical implant communication service band |
CA2468577A1 (en) | 2001-11-28 | 2003-06-05 | Phemi Inc. | Methods and apparatus for automated interactive medical management |
WO2003049424A1 (en) | 2001-12-03 | 2003-06-12 | Nikon Corporation | Electronic apparatus, electronic camera, electronic device, image display apparatus, and image transmission system |
US7729776B2 (en) | 2001-12-19 | 2010-06-01 | Cardiac Pacemakers, Inc. | Implantable medical device with two or more telemetry systems |
US7204823B2 (en) | 2001-12-19 | 2007-04-17 | Medtronic Minimed, Inc. | Medication delivery system and monitor |
US20050027182A1 (en) | 2001-12-27 | 2005-02-03 | Uzair Siddiqui | System for monitoring physiological characteristics |
US7022072B2 (en) | 2001-12-27 | 2006-04-04 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US7399277B2 (en) | 2001-12-27 | 2008-07-15 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US20080255438A1 (en) | 2001-12-27 | 2008-10-16 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US6980852B2 (en) | 2002-01-25 | 2005-12-27 | Subqiview Inc. | Film barrier dressing for intravascular tissue monitoring system |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US9247901B2 (en) * | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
EP1487519B1 (en) | 2002-02-26 | 2013-06-12 | TecPharma Licensing AG | Insertion device for an insertion set and method of using the same |
US20030212379A1 (en) | 2002-02-26 | 2003-11-13 | Bylund Adam David | Systems and methods for remotely controlling medication infusion and analyte monitoring |
US6998247B2 (en) | 2002-03-08 | 2006-02-14 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
US6936006B2 (en) | 2002-03-22 | 2005-08-30 | Novo Nordisk, A/S | Atraumatic insertion of a subcutaneous device |
GB2388898B (en) | 2002-04-02 | 2005-10-05 | Inverness Medical Ltd | Integrated sample testing meter |
US7027848B2 (en) | 2002-04-04 | 2006-04-11 | Inlight Solutions, Inc. | Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte |
US7410468B2 (en) | 2002-04-19 | 2008-08-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7713214B2 (en) | 2002-04-19 | 2010-05-11 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing |
US7153265B2 (en) | 2002-04-22 | 2006-12-26 | Medtronic Minimed, Inc. | Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance |
EP1498067A1 (en) | 2002-04-25 | 2005-01-19 | Matsushita Electric Industrial Co., Ltd. | Dosage determination supporting device, injector, and health management supporting system |
GB2388715B (en) | 2002-05-13 | 2005-08-03 | Splashpower Ltd | Improvements relating to the transfer of electromagnetic power |
US7015817B2 (en) | 2002-05-14 | 2006-03-21 | Shuan Michael Copley | Personal tracking device |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US6865407B2 (en) | 2002-07-11 | 2005-03-08 | Optical Sensors, Inc. | Calibration technique for non-invasive medical devices |
US20040010207A1 (en) | 2002-07-15 | 2004-01-15 | Flaherty J. Christopher | Self-contained, automatic transcutaneous physiologic sensing system |
JP2004054394A (en) | 2002-07-17 | 2004-02-19 | Toshiba Corp | Radio information processing system, radio information recording medium, radio information processor and communication method for radio information processing system |
EP1543322A4 (en) | 2002-07-19 | 2008-07-09 | Smiths Detection Pasadena Inc | Non-specific sensor array detectors |
EP2327359B1 (en) | 2002-08-13 | 2015-01-21 | University Of Virginia Patent Foundation | Method, system, and computer program product for processing of self-monitoring blood glucose (smbg) data to enhance diabetic self-management |
US6865641B2 (en) | 2002-08-29 | 2005-03-08 | International Business Machines Corporation | Method and apparatus for non-volatile display of information for an electronic device |
US7404796B2 (en) | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
US7192405B2 (en) | 2002-09-30 | 2007-03-20 | Becton, Dickinson And Company | Integrated lancet and bodily fluid sensor |
US20090177068A1 (en) | 2002-10-09 | 2009-07-09 | Stivoric John M | Method and apparatus for providing derived glucose information utilizing physiological and/or contextual parameters |
EP1575656B1 (en) | 2002-10-11 | 2009-06-17 | Becton, Dickinson and Company | Insulin delivery system with sensor |
EP1565102A4 (en) | 2002-10-15 | 2008-05-28 | Medtronic Inc | Synchronization and calibration of clocks for a medical device and calibrated clock |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US7572237B2 (en) | 2002-11-06 | 2009-08-11 | Abbott Diabetes Care Inc. | Automatic biological analyte testing meter with integrated lancing device and methods of use |
EP1424637A1 (en) | 2002-11-29 | 2004-06-02 | Instrumentarium Corporation | Artifact removal from an electric signal |
US7009511B2 (en) | 2002-12-17 | 2006-03-07 | Cardiac Pacemakers, Inc. | Repeater device for communications with an implantable medical device |
US20040122353A1 (en) | 2002-12-19 | 2004-06-24 | Medtronic Minimed, Inc. | Relay device for transferring information between a sensor system and a fluid delivery system |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US7413749B2 (en) | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
US9872890B2 (en) | 2003-03-19 | 2018-01-23 | Paul C. Davidson | Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
US20040199056A1 (en) | 2003-04-03 | 2004-10-07 | International Business Machines Corporation | Body monitoring using local area wireless interfaces |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US20040204868A1 (en) | 2003-04-09 | 2004-10-14 | Maynard John D. | Reduction of errors in non-invasive tissue sampling |
AU2004232289A1 (en) | 2003-04-18 | 2004-11-04 | Insulet Corporation | User interface for infusion pump remote controller and method of using the same |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US20040254433A1 (en) | 2003-06-12 | 2004-12-16 | Bandis Steven D. | Sensor introducer system, apparatus and method |
US7155290B2 (en) | 2003-06-23 | 2006-12-26 | Cardiac Pacemakers, Inc. | Secure long-range telemetry for implantable medical device |
US7510564B2 (en) | 2003-06-27 | 2009-03-31 | Abbott Diabetes Care Inc. | Lancing device |
US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
WO2005007223A2 (en) | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
EP1652088B1 (en) | 2003-07-25 | 2017-09-13 | Philips Intellectual Property & Standards GmbH | Method and device for monitoring a system |
US7460898B2 (en) | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7074307B2 (en) | 2003-07-25 | 2006-07-11 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
US7467003B2 (en) | 2003-12-05 | 2008-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20050176136A1 (en) | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
US7108778B2 (en) | 2003-07-25 | 2006-09-19 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
EP1648298A4 (en) | 2003-07-25 | 2010-01-13 | Dexcom Inc | Oxygen enhancing membrane systems for implantable devices |
US7366556B2 (en) | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7424318B2 (en) | 2003-12-05 | 2008-09-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
US7494465B2 (en) | 2004-07-13 | 2009-02-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US20100168542A1 (en) | 2003-08-01 | 2010-07-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7959569B2 (en) | 2003-08-01 | 2011-06-14 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8626257B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | Analyte sensor |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7519408B2 (en) | 2003-11-19 | 2009-04-14 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US6931327B2 (en) | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7813809B2 (en) | 2004-06-10 | 2010-10-12 | Medtronic, Inc. | Implantable pulse generator for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue |
US7148803B2 (en) | 2003-10-24 | 2006-12-12 | Symbol Technologies, Inc. | Radio frequency identification (RFID) based sensor networks |
US20050090607A1 (en) | 2003-10-28 | 2005-04-28 | Dexcom, Inc. | Silicone composition for biocompatible membrane |
JP2007512588A (en) | 2003-10-29 | 2007-05-17 | ノボ・ノルデイスク・エー/エス | Medical advice system |
US6928380B2 (en) | 2003-10-30 | 2005-08-09 | International Business Machines Corporation | Thermal measurements of electronic devices during operation |
US20050096516A1 (en) | 2003-10-30 | 2005-05-05 | Orhan Soykan | Optical detector of organic analyte |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
US20090012376A1 (en) | 2003-11-03 | 2009-01-08 | Children's Medical Center Corporation | Continuous Analyte Monitor and Method of Using Same |
KR100519776B1 (en) | 2003-11-24 | 2005-10-07 | 삼성전자주식회사 | Method and apparatus for converting resolution of video signal |
US20050113886A1 (en) | 2003-11-24 | 2005-05-26 | Fischell David R. | Implantable medical system with long range telemetry |
US20050113648A1 (en) | 2003-11-24 | 2005-05-26 | Soohyun Yang | Bidirectional monitoring system capable of a medical diagnosis and a commercial broadcast |
US20080200788A1 (en) | 2006-10-04 | 2008-08-21 | Dexcorn, Inc. | Analyte sensor |
US20080197024A1 (en) | 2003-12-05 | 2008-08-21 | Dexcom, Inc. | Analyte sensor |
WO2005057168A2 (en) | 2003-12-05 | 2005-06-23 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US20100185071A1 (en) | 2003-12-05 | 2010-07-22 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8425417B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8364230B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8425416B2 (en) | 2006-10-04 | 2013-04-23 | Dexcom, Inc. | Analyte sensor |
EP1711802B1 (en) | 2003-12-08 | 2010-07-14 | DexCom, Inc. | Systems and methods for improving electrochemical analyte sensors |
WO2005057175A2 (en) | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US7637868B2 (en) | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
CN1914823A (en) | 2004-01-27 | 2007-02-14 | 阿尔特维拉有限公司 | Diagnostic radio frequency identification sensors and applications thereof |
US7580812B2 (en) | 2004-01-28 | 2009-08-25 | Honeywell International Inc. | Trending system and method using window filtering |
US7699964B2 (en) | 2004-02-09 | 2010-04-20 | Abbott Diabetes Care Inc. | Membrane suitable for use in an analyte sensor, analyte sensor, and associated method |
US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
US7364592B2 (en) | 2004-02-12 | 2008-04-29 | Dexcom, Inc. | Biointerface membrane with macro-and micro-architecture |
WO2005089103A2 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US6983884B2 (en) | 2004-02-19 | 2006-01-10 | Neoteric Technology, Limited | Method and apparatus for monitoring transfusion of blood |
US20060154642A1 (en) | 2004-02-20 | 2006-07-13 | Scannell Robert F Jr | Medication & health, environmental, and security monitoring, alert, intervention, information and network system with associated and supporting apparatuses |
JP3590053B1 (en) | 2004-02-24 | 2004-11-17 | 株式会社日立製作所 | Blood glucose measurement device |
DE602005013750D1 (en) | 2004-02-26 | 2009-05-20 | Diabetes Tools Sweden Ab | METABOLISM MONITORING, METHOD AND DEVICE FOR AERSON |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US7039538B2 (en) | 2004-03-08 | 2006-05-02 | Nellcor Puritant Bennett Incorporated | Pulse oximeter with separate ensemble averaging for oxygen saturation and heart rate |
GB0405798D0 (en) | 2004-03-15 | 2004-04-21 | E San Ltd | Medical data display |
US7831828B2 (en) | 2004-03-15 | 2010-11-09 | Cardiac Pacemakers, Inc. | System and method for securely authenticating a data exchange session with an implantable medical device |
CA2560323C (en) | 2004-03-22 | 2014-01-07 | Bodymedia, Inc. | Non-invasive temperature monitoring device |
JP2007535974A (en) | 2004-03-26 | 2007-12-13 | ノボ・ノルデイスク・エー/エス | Display device for related data of diabetic patients |
US6971274B2 (en) | 2004-04-02 | 2005-12-06 | Sierra Instruments, Inc. | Immersible thermal mass flow meter |
US7815569B2 (en) | 2004-04-21 | 2010-10-19 | University Of Virginia Patent Foundation | Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices |
US20050245799A1 (en) | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
WO2005113036A1 (en) | 2004-05-13 | 2005-12-01 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
US7125382B2 (en) | 2004-05-20 | 2006-10-24 | Digital Angel Corporation | Embedded bio-sensor system |
US6999854B2 (en) | 2004-05-28 | 2006-02-14 | International Business Machines Corporation | Medical infusion pump capable of learning bolus time patterns and providing bolus alerts |
US7118667B2 (en) | 2004-06-02 | 2006-10-10 | Jin Po Lee | Biosensors having improved sample application and uses thereof |
US20060010098A1 (en) | 2004-06-04 | 2006-01-12 | Goodnow Timothy T | Diabetes care host-client architecture and data management system |
US7289855B2 (en) | 2004-06-09 | 2007-10-30 | Medtronic, Inc. | Implantable medical device package antenna |
US20070060979A1 (en) | 2004-06-10 | 2007-03-15 | Ndi Medical, Llc | Implantable pulse generator systems and methods for providing functional and / or therapeutic stimulation of muscles and / or nerves and / or central nervous system tissue |
US7623988B2 (en) | 2004-06-23 | 2009-11-24 | Cybiocare Inc. | Method and apparatus for the monitoring of clinical states |
DE102004031092A1 (en) | 2004-06-28 | 2006-01-12 | Giesecke & Devrient Gmbh | transponder unit |
US20060001538A1 (en) | 2004-06-30 | 2006-01-05 | Ulrich Kraft | Methods of monitoring the concentration of an analyte |
US20060001551A1 (en) | 2004-06-30 | 2006-01-05 | Ulrich Kraft | Analyte monitoring system with wireless alarm |
US20060015020A1 (en) | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20060270922A1 (en) | 2004-07-13 | 2006-11-30 | Brauker James H | Analyte sensor |
US20060020192A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20080242961A1 (en) | 2004-07-13 | 2008-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7344500B2 (en) | 2004-07-27 | 2008-03-18 | Medtronic Minimed, Inc. | Sensing system with auxiliary display |
US8313433B2 (en) | 2004-08-06 | 2012-11-20 | Medtronic Minimed, Inc. | Medical data management system and process |
JP5032321B2 (en) | 2004-08-31 | 2012-09-26 | ライフスキャン・スコットランド・リミテッド | Manufacturing method of automatic calibration sensor |
EP1799101A4 (en) | 2004-09-02 | 2008-11-19 | Proteus Biomedical Inc | Methods and apparatus for tissue activation and monitoring |
US20080312859A1 (en) | 2004-09-03 | 2008-12-18 | Novo Nordisk A/S | Method of Calibrating a System for Measuring the Concentration of Substances in Body and an Apparatus for Exercising the Method |
US7978063B2 (en) | 2004-12-13 | 2011-07-12 | Koninklijke Philips Electronics N.V. | Wireless network having body coupled communication for mobile patient monitoring |
US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US20070027381A1 (en) | 2005-07-29 | 2007-02-01 | Therasense, Inc. | Inserter and methods of use |
US20090082693A1 (en) | 2004-12-29 | 2009-03-26 | Therasense, Inc. | Method and apparatus for providing temperature sensor module in a data communication system |
US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
CN101137320B (en) | 2004-12-29 | 2012-10-03 | 生命扫描苏格兰有限公司 | Method of inputting data into an analyte testing device |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US20060166629A1 (en) | 2005-01-24 | 2006-07-27 | Therasense, Inc. | Method and apparatus for providing EMC Class-B compliant RF transmitter for data monitoring an detection systems |
US20060173260A1 (en) | 2005-01-31 | 2006-08-03 | Gmms Ltd | System, device and method for diabetes treatment and monitoring |
US7547281B2 (en) | 2005-02-01 | 2009-06-16 | Medtronic Minimed, Inc. | Algorithm sensor augmented bolus estimator for semi-closed loop infusion system |
US7499002B2 (en) | 2005-02-08 | 2009-03-03 | International Business Machines Corporation | Retractable string interface for stationary and portable devices |
EP1850747A2 (en) | 2005-02-11 | 2007-11-07 | The University Court Of The University Of Glasgow | Sensing device, apparatus and system, and method for operating the same |
KR100638727B1 (en) | 2005-02-28 | 2006-10-30 | 삼성전기주식회사 | Concurrent transceiver for zigbee and bluetooth |
US20090076360A1 (en) | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
AU2006222889A1 (en) | 2005-03-15 | 2006-09-21 | Entelos, Inc. | Apparatus and method for computer modeling type 1 diabetes |
CN101180093B (en) | 2005-03-21 | 2012-07-18 | 雅培糖尿病护理公司 | Method and system for providing integrated medication infusion and analyte monitoring system |
US7889069B2 (en) | 2005-04-01 | 2011-02-15 | Codman & Shurtleff, Inc. | Wireless patient monitoring system |
WO2006110193A2 (en) | 2005-04-08 | 2006-10-19 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
GB2425601B (en) | 2005-04-26 | 2008-01-30 | Bio Nano Sensium Technologies | Sensor configuration |
US20060247985A1 (en) | 2005-04-29 | 2006-11-02 | Therasense, Inc. | Method and system for monitoring consumable item usage and providing replenishment thereof |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
US20060264779A1 (en) | 2005-05-09 | 2006-11-23 | Kemp Timothy M | Fluidic medical devices and uses thereof |
US7806854B2 (en) | 2005-05-13 | 2010-10-05 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
US7541935B2 (en) | 2005-05-19 | 2009-06-02 | Proacticare Llc | System and methods for monitoring caregiver performance |
WO2006130854A2 (en) | 2005-06-02 | 2006-12-07 | Isense Corporation | Use of multiple data points and filtering in an analyte sensor |
US20080071580A1 (en) | 2005-06-03 | 2008-03-20 | Marcus Alan O | System and method for medical evaluation and monitoring |
US20060272652A1 (en) | 2005-06-03 | 2006-12-07 | Medtronic Minimed, Inc. | Virtual patient software system for educating and treating individuals with diabetes |
US20070033074A1 (en) | 2005-06-03 | 2007-02-08 | Medtronic Minimed, Inc. | Therapy management system |
CA2653616C (en) | 2005-06-08 | 2013-02-12 | Philip Michael Sher | Fluctuating blood glucose notification threshold profiles and methods of use |
US8251904B2 (en) | 2005-06-09 | 2012-08-28 | Roche Diagnostics Operations, Inc. | Device and method for insulin dosing |
US7413124B2 (en) | 2005-07-19 | 2008-08-19 | 3M Innovative Properties Company | RFID reader supporting one-touch search functionality |
US20070066956A1 (en) | 2005-07-27 | 2007-03-22 | Medtronic Minimed, Inc. | Systems and methods for entering temporary basal rate pattern in an infusion device |
TWI417543B (en) | 2005-08-05 | 2013-12-01 | Bayer Healthcare Llc | Meters and method of using meters having a multi-level user interface with predefined levels of user features |
US20070093786A1 (en) | 2005-08-16 | 2007-04-26 | Medtronic Minimed, Inc. | Watch controller for a medical device |
US20070060869A1 (en) | 2005-08-16 | 2007-03-15 | Tolle Mike C V | Controller device for an infusion pump |
US9089713B2 (en) | 2005-08-31 | 2015-07-28 | Michael Sasha John | Methods and systems for semi-automatic adjustment of medical monitoring and treatment |
CN101365374B (en) | 2005-08-31 | 2011-11-16 | 弗吉尼亚大学专利基金委员会 | Improving accuracy of continuous glucose sensors |
US8965509B2 (en) | 2005-08-31 | 2015-02-24 | Michael Sasha John | Methods and systems for semi-automatic adjustment of medical monitoring and treatment |
WO2007028271A2 (en) | 2005-09-09 | 2007-03-15 | F. Hoffmann-La Roche Ag | A system, tools, devices and a program for diabetes care |
US9072476B2 (en) | 2005-09-23 | 2015-07-07 | Medtronic Minimed, Inc. | Flexible sensor apparatus |
US20070078314A1 (en) | 2005-09-30 | 2007-04-05 | Grounsell Richard L | System and method for measuring and predicting insulin dosing rates |
US7756561B2 (en) | 2005-09-30 | 2010-07-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US7468125B2 (en) | 2005-10-17 | 2008-12-23 | Lifescan, Inc. | System and method of processing a current sample for calculating a glucose concentration |
US20090054747A1 (en) | 2005-10-31 | 2009-02-26 | Abbott Diabetes Care, Inc. | Method and system for providing analyte sensor tester isolation |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
EP3064236B1 (en) | 2005-11-08 | 2020-02-05 | Bigfoot Biomedical, Inc. | Method and system for manual and autonomous control of an infusion pump |
US20070173706A1 (en) | 2005-11-11 | 2007-07-26 | Isense Corporation | Method and apparatus for insertion of a sensor |
WO2007062173A1 (en) | 2005-11-22 | 2007-05-31 | Vocollect Healthcare Systems, Inc. | Advanced diabetes management system (adms) |
US7963917B2 (en) | 2005-12-05 | 2011-06-21 | Echo Therapeutics, Inc. | System and method for continuous non-invasive glucose monitoring |
US7941200B2 (en) | 2005-12-08 | 2011-05-10 | Roche Diagnostics Operations, Inc. | System and method for determining drug administration information |
US8160670B2 (en) | 2005-12-28 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
EP1968432A4 (en) | 2005-12-28 | 2009-10-21 | Abbott Diabetes Care Inc | Medical device insertion |
US8515518B2 (en) | 2005-12-28 | 2013-08-20 | Abbott Diabetes Care Inc. | Analyte monitoring |
US7785256B1 (en) | 2006-01-11 | 2010-08-31 | Pacesetter, Inc. | Method and system for displaying patient activity data using Poincaré and intensity plot |
EP2004796B1 (en) | 2006-01-18 | 2015-04-08 | DexCom, Inc. | Membranes for an analyte sensor |
US20070179349A1 (en) | 2006-01-19 | 2007-08-02 | Hoyme Kenneth P | System and method for providing goal-oriented patient management based upon comparative population data analysis |
US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
US7872574B2 (en) | 2006-02-01 | 2011-01-18 | Innovation Specialists, Llc | Sensory enhancement systems and methods in personal electronic devices |
EP2338547B1 (en) | 2006-02-09 | 2013-04-17 | DEKA Products Limited Partnership | Fluid delivery systems |
EP1993637A2 (en) | 2006-02-15 | 2008-11-26 | Medingo Ltd. | Systems and methods for sensing analyte and dispensing therapeutic fluid |
AU2007221172A1 (en) | 2006-02-27 | 2007-09-07 | Edwards Lifesciences Corporation | Flux limiting membrane for intravenous amperometric biosensor |
US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US9326709B2 (en) | 2010-03-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
CA2649563C (en) | 2006-04-20 | 2015-02-17 | Manfred Ebner | Method for transmitting data in a blood glucose system and corresponding blood glucose system |
US20070255126A1 (en) | 2006-04-28 | 2007-11-01 | Moberg Sheldon B | Data communication in networked fluid infusion systems |
US8380300B2 (en) | 2006-04-28 | 2013-02-19 | Medtronic, Inc. | Efficacy visualization |
WO2007128144A1 (en) | 2006-05-10 | 2007-11-15 | F. Hoffmann-La Roche Ag | Infusion apparatus with a data storage device |
US20080071158A1 (en) | 2006-06-07 | 2008-03-20 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
US20080177149A1 (en) | 2006-06-16 | 2008-07-24 | Stefan Weinert | System and method for collecting patient information from which diabetes therapy may be determined |
US20080004601A1 (en) | 2006-06-28 | 2008-01-03 | Abbott Diabetes Care, Inc. | Analyte Monitoring and Therapy Management System and Methods Therefor |
US9119582B2 (en) | 2006-06-30 | 2015-09-01 | Abbott Diabetes Care, Inc. | Integrated analyte sensor and infusion device and methods therefor |
US20090105571A1 (en) | 2006-06-30 | 2009-04-23 | Abbott Diabetes Care, Inc. | Method and System for Providing Data Communication in Data Management Systems |
ES2831604T3 (en) | 2006-07-07 | 2021-06-09 | Hoffmann La Roche | Fluid Management Device and Operating Procedures |
US8932216B2 (en) | 2006-08-07 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for providing data management in integrated analyte monitoring and infusion system |
US8206296B2 (en) | 2006-08-07 | 2012-06-26 | Abbott Diabetes Care Inc. | Method and system for providing integrated analyte monitoring and infusion system therapy management |
US9056165B2 (en) | 2006-09-06 | 2015-06-16 | Medtronic Minimed, Inc. | Intelligent therapy recommendation algorithm and method of using the same |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8275438B2 (en) | 2006-10-04 | 2012-09-25 | Dexcom, Inc. | Analyte sensor |
US8449464B2 (en) | 2006-10-04 | 2013-05-28 | Dexcom, Inc. | Analyte sensor |
US8478377B2 (en) | 2006-10-04 | 2013-07-02 | Dexcom, Inc. | Analyte sensor |
US8298142B2 (en) | 2006-10-04 | 2012-10-30 | Dexcom, Inc. | Analyte sensor |
US8562528B2 (en) | 2006-10-04 | 2013-10-22 | Dexcom, Inc. | Analyte sensor |
US8447376B2 (en) | 2006-10-04 | 2013-05-21 | Dexcom, Inc. | Analyte sensor |
US8255026B1 (en) | 2006-10-12 | 2012-08-28 | Masimo Corporation, Inc. | Patient monitor capable of monitoring the quality of attached probes and accessories |
US20080092638A1 (en) | 2006-10-19 | 2008-04-24 | Bayer Healthcare Llc | Wireless analyte monitoring system |
CN102772212A (en) | 2006-10-26 | 2012-11-14 | 雅培糖尿病护理公司 | Method, device and system for detection of sensitivity decline in analyte sensors |
EP1918837A1 (en) | 2006-10-31 | 2008-05-07 | F. Hoffmann-La Roche AG | Method for processing a chronological sequence of measurements of a time dependent parameter |
FI20065735A0 (en) | 2006-11-20 | 2006-11-20 | Salla Koski | Measurement, monitoring and management system and its constituent equipment |
US20080139910A1 (en) | 2006-12-06 | 2008-06-12 | Metronic Minimed, Inc. | Analyte sensor and method of using the same |
US9034860B2 (en) | 2006-12-07 | 2015-05-19 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing low-substituted hydroxypropyl cellulose |
WO2008071218A1 (en) | 2006-12-14 | 2008-06-19 | Egomedical Swiss Ag | Monitoring device |
US20080154513A1 (en) | 2006-12-21 | 2008-06-26 | University Of Virginia Patent Foundation | Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes |
US7946985B2 (en) | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
US20080161666A1 (en) | 2006-12-29 | 2008-07-03 | Abbott Diabetes Care, Inc. | Analyte devices and methods |
US7734323B2 (en) | 2007-01-24 | 2010-06-08 | Smiths Medical Asd, Inc. | Correction factor testing using frequent blood glucose input |
US10154804B2 (en) | 2007-01-31 | 2018-12-18 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
US9597019B2 (en) | 2007-02-09 | 2017-03-21 | Lifescan, Inc. | Method of ensuring date and time on a test meter is accurate |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US20090093687A1 (en) | 2007-03-08 | 2009-04-09 | Telfort Valery G | Systems and methods for determining a physiological condition using an acoustic monitor |
US8758245B2 (en) | 2007-03-20 | 2014-06-24 | Lifescan, Inc. | Systems and methods for pattern recognition in diabetes management |
US20080234943A1 (en) | 2007-03-20 | 2008-09-25 | Pinaki Ray | Computer program for diabetes management |
US9029157B2 (en) | 2007-04-12 | 2015-05-12 | Nipro Diagnostics, Inc. | Error detection and rejection for a diagnostic testing system |
WO2008128210A1 (en) | 2007-04-14 | 2008-10-23 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2683962C (en) | 2007-04-14 | 2017-06-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2683721C (en) | 2007-04-14 | 2017-05-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
CA2683953C (en) | 2007-04-14 | 2016-08-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
WO2009096992A1 (en) | 2007-04-14 | 2009-08-06 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
EP2146624B1 (en) | 2007-04-14 | 2020-03-25 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US20080269714A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
US20080269723A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20080312845A1 (en) | 2007-05-14 | 2008-12-18 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20080287755A1 (en) | 2007-05-17 | 2008-11-20 | Isense Corporation | Method and apparatus for trend alert calculation and display |
US7972296B2 (en) | 2007-10-10 | 2011-07-05 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
US20080294024A1 (en) | 2007-05-24 | 2008-11-27 | Cosentino Daniel L | Glucose meter system and monitor |
US20080300572A1 (en) | 2007-06-01 | 2008-12-04 | Medtronic Minimed, Inc. | Wireless monitor for a personal medical device system |
US20080306444A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
EP2166929B1 (en) | 2007-06-15 | 2012-12-19 | F. Hoffmann-La Roche AG | Visualization of a parameter which is measured on the human body |
EP2006786B1 (en) | 2007-06-18 | 2018-05-09 | Roche Diabetes Care GmbH | Method and glucose monitoring system for monitoring individual metabolic response and for generating nutritional feedback |
US9754078B2 (en) | 2007-06-21 | 2017-09-05 | Immersion Corporation | Haptic health feedback monitoring |
CA2687562C (en) | 2007-06-27 | 2015-11-24 | F. Hoffmann-La Roche Ag | System and method for developing patient specific therapies based on modeling of patient physiology |
US20090005729A1 (en) | 2007-06-27 | 2009-01-01 | Animas Corporation | Medical infusion pumps |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
EP2186035B1 (en) | 2007-06-29 | 2018-12-26 | Roche Diabetes Care GmbH | Apparatus and method for remotely controlling an ambulatory medical device |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US7768386B2 (en) | 2007-07-31 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20090036760A1 (en) | 2007-07-31 | 2009-02-05 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7731658B2 (en) | 2007-08-16 | 2010-06-08 | Cardiac Pacemakers, Inc. | Glycemic control monitoring using implantable medical device |
US9968742B2 (en) | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
US20090063402A1 (en) | 2007-08-31 | 2009-03-05 | Abbott Diabetes Care, Inc. | Method and System for Providing Medication Level Determination |
CA2702113A1 (en) | 2007-10-11 | 2009-04-16 | Optiscan Biomedical Corporation | Synchronization and configuration of patient monitoring devices |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US8216138B1 (en) | 2007-10-23 | 2012-07-10 | Abbott Diabetes Care Inc. | Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7783442B2 (en) | 2007-10-31 | 2010-08-24 | Medtronic Minimed, Inc. | System and methods for calibrating physiological characteristic sensors |
IL194966A0 (en) | 2007-10-31 | 2009-08-03 | Animas Corp | User interface for insulin infusion device |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US20090164190A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Physiological condition simulation device and method |
US20090163855A1 (en) | 2007-12-24 | 2009-06-25 | Medtronic Minimed, Inc. | Infusion system with adaptive user interface |
WO2009097450A1 (en) | 2008-01-30 | 2009-08-06 | Dexcom. Inc. | Continuous cardiac marker sensor system |
EP2090996A1 (en) | 2008-02-16 | 2009-08-19 | Roche Diagnostics GmbH | Medical device |
JP5091881B2 (en) | 2008-02-20 | 2012-12-05 | カルソニックカンセイ株式会社 | Collision detection device |
WO2009105337A2 (en) | 2008-02-20 | 2009-08-27 | Dexcom, Inc. | Continuous medicament sensor system for in vivo use |
CA2715628A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8317699B2 (en) | 2008-02-29 | 2012-11-27 | Roche Diagnostics Operations, Inc. | Device and method for assessing blood glucose control |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US20090242399A1 (en) | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
EP3387993A3 (en) | 2008-03-28 | 2018-11-14 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20110031986A1 (en) | 2008-04-11 | 2011-02-10 | Navakanta Bhat | Sub-Threshold Capfet Sensor for Sensing Analyte, A Method and System Thereof |
US7783342B2 (en) | 2008-04-21 | 2010-08-24 | International Business Machines Corporation | System and method for inferring disease similarity by shape matching of ECG time series |
US8207860B2 (en) | 2008-04-28 | 2012-06-26 | Medtronic Minimed, Inc. | Automobile physiological monitoring system and method for using the same |
US7938797B2 (en) | 2008-05-05 | 2011-05-10 | Asante Solutions, Inc. | Infusion pump system |
US7826382B2 (en) | 2008-05-30 | 2010-11-02 | Abbott Diabetes Care Inc. | Close proximity communication device and methods |
US8394637B2 (en) | 2008-06-02 | 2013-03-12 | Roche Diagnostics Operations, Inc. | Handheld analyzer for testing a sample |
US8876755B2 (en) | 2008-07-14 | 2014-11-04 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
CA2738389C (en) | 2008-09-15 | 2017-01-17 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
US20100095229A1 (en) | 2008-09-18 | 2010-04-15 | Abbott Diabetes Care, Inc. | Graphical user interface for glucose monitoring system |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US8287487B2 (en) | 2008-10-15 | 2012-10-16 | Asante Solutions, Inc. | Infusion pump system and methods |
US8597570B2 (en) | 2008-11-04 | 2013-12-03 | Panasonic Corporation | Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program |
US20100331644A1 (en) | 2008-11-07 | 2010-12-30 | Dexcom, Inc. | Housing for an intravascular sensor |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
JP5657559B2 (en) | 2008-11-26 | 2015-01-21 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | Method, system and computer program for tracking and recording blood glucose fluctuations in diabetes |
US9320470B2 (en) | 2008-12-31 | 2016-04-26 | Medtronic Minimed, Inc. | Method and/or system for sensor artifact filtering |
US8974439B2 (en) | 2009-01-02 | 2015-03-10 | Asante Solutions, Inc. | Infusion pump system and methods |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
WO2010091102A1 (en) | 2009-02-04 | 2010-08-12 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8394246B2 (en) | 2009-02-23 | 2013-03-12 | Roche Diagnostics Operations, Inc. | System and method for the electrochemical measurement of an analyte employing a remote sensor |
DK3912551T3 (en) | 2009-02-26 | 2023-10-30 | Abbott Diabetes Care Inc | Procedure for calibrating an analyte sensor |
US20100249530A1 (en) | 2009-03-24 | 2010-09-30 | Medtronic Minimed, Inc. | Bolus Estimator with Image Capture Device |
WO2010111660A1 (en) | 2009-03-27 | 2010-09-30 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US8497777B2 (en) * | 2009-04-15 | 2013-07-30 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
EP2419015A4 (en) | 2009-04-16 | 2014-08-20 | Abbott Diabetes Care Inc | Analyte sensor calibration management |
WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US20100274515A1 (en) | 2009-04-28 | 2010-10-28 | Abbott Diabetes Care Inc. | Dynamic Analyte Sensor Calibration Based On Sensor Stability Profile |
WO2010127187A1 (en) | 2009-04-29 | 2010-11-04 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
EP2425209A4 (en) | 2009-04-29 | 2013-01-09 | Abbott Diabetes Care Inc | Method and system for providing real time analyte sensor calibration with retrospective backfill |
US20110004085A1 (en) | 2009-04-30 | 2011-01-06 | Dexcom, Inc. | Performance reports associated with continuous sensor data from multiple analysis time periods |
US20100305965A1 (en) | 2009-05-29 | 2010-12-02 | Abbott Diabetes Care Inc. | Integrated report generation of medical data with varying levels of information |
US8595607B2 (en) | 2009-06-04 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and system for updating a medical device |
US9218453B2 (en) | 2009-06-29 | 2015-12-22 | Roche Diabetes Care, Inc. | Blood glucose management and interface systems and methods |
WO2011003035A2 (en) | 2009-07-02 | 2011-01-06 | Dexcom, Inc. | Analyte sensor |
US20110010257A1 (en) | 2009-07-09 | 2011-01-13 | Medtronic Minimed, Inc. | Providing contextually relevant advertisements and e-commerce features in a personal medical device system |
US20110009813A1 (en) | 2009-07-09 | 2011-01-13 | Medtronic Minimed, Inc. | Panning a display of a portable medical device |
US20120165626A1 (en) | 2009-07-13 | 2012-06-28 | Irina Finkelshtein V | Devices, methods, and kits for determining analyte concentrations |
LT3689237T (en) | 2009-07-23 | 2021-09-27 | Abbott Diabetes Care, Inc. | Method of manufacturing and system for continuous analyte measurement |
DK3988470T3 (en) | 2009-08-31 | 2023-08-28 | Abbott Diabetes Care Inc | Display devices for a medical device |
LT3920471T (en) | 2009-09-08 | 2024-02-26 | Abbott Diabetes Care, Inc. | Methods and articles of manufacture for hosting a safety critical application on an uncontrolled data processing device |
US20110077469A1 (en) | 2009-09-27 | 2011-03-31 | Blocker Richard A | Systems and methods for utilizing prolonged self monitoring in the analysis of chronic ailment treatments |
WO2011041469A1 (en) | 2009-09-29 | 2011-04-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
EP2482724A2 (en) | 2009-09-30 | 2012-08-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8185181B2 (en) | 2009-10-30 | 2012-05-22 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US20110123971A1 (en) | 2009-11-20 | 2011-05-26 | Medivoce, Inc. | Electronic Medical Voice Instruction System |
US9949672B2 (en) | 2009-12-17 | 2018-04-24 | Ascensia Diabetes Care Holdings Ag | Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels |
US8803688B2 (en) | 2010-01-07 | 2014-08-12 | Lisa Halff | System and method responsive to an event detected at a glucose monitoring device |
US20110163880A1 (en) | 2010-01-07 | 2011-07-07 | Lisa Halff | System and method responsive to an alarm event detected at an insulin delivery device |
CA2728831A1 (en) | 2010-01-22 | 2011-07-22 | Lifescan, Inc. | Diabetes management unit, method, and system |
US20110184268A1 (en) * | 2010-01-22 | 2011-07-28 | Abbott Diabetes Care Inc. | Method, Device and System for Providing Analyte Sensor Calibration |
US9041730B2 (en) | 2010-02-12 | 2015-05-26 | Dexcom, Inc. | Receivers for analyzing and displaying sensor data |
US20110208027A1 (en) | 2010-02-23 | 2011-08-25 | Roche Diagnostics Operations, Inc. | Methods And Systems For Providing Therapeutic Guidelines To A Person Having Diabetes |
WO2011133768A1 (en) | 2010-04-22 | 2011-10-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods related to analyte monitoring and management |
WO2011149857A1 (en) | 2010-05-24 | 2011-12-01 | Abbott Diabetes Care Inc. | Method and system for updating a medical device |
US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
WO2011163519A2 (en) | 2010-06-25 | 2011-12-29 | Dexcom, Inc. | Systems and methods for communicating sensor data between communication devices |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
EP3632308B1 (en) | 2010-09-29 | 2023-12-06 | Dexcom, Inc. | Advanced continuous analyte monitoring system |
US9241631B2 (en) | 2010-10-27 | 2016-01-26 | Dexcom, Inc. | Continuous analyte monitor data recording device operable in a blinded mode |
US20120165640A1 (en) | 2010-12-23 | 2012-06-28 | Roche Diagnostics Operations, Inc. | Structured blood glucose testing performed on handheld diabetes management devices |
EP2680754B1 (en) | 2011-02-28 | 2019-04-24 | Abbott Diabetes Care, Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
WO2013022775A1 (en) | 2011-08-05 | 2013-02-14 | Dexcom, Inc. | Systems and methods for detecting glucose level data patterns |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US20130235166A1 (en) | 2012-03-07 | 2013-09-12 | Cambridge Silicon Radio Limited | Synchronisation method |
-
2012
- 2012-11-21 WO PCT/US2012/066414 patent/WO2013078426A2/en active Application Filing
- 2012-11-21 US US13/683,996 patent/US9339217B2/en not_active Expired - Fee Related
-
2016
- 2016-04-29 US US15/143,413 patent/US10082493B2/en active Active
-
2018
- 2018-08-23 US US16/111,099 patent/US11391723B2/en active Active
-
2022
- 2022-07-19 US US17/868,386 patent/US20230007916A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013078426A3 (en) | 2016-05-19 |
US10082493B2 (en) | 2018-09-25 |
WO2013078426A2 (en) | 2013-05-30 |
US9339217B2 (en) | 2016-05-17 |
US20160238589A1 (en) | 2016-08-18 |
US20130137953A1 (en) | 2013-05-30 |
US20180364215A1 (en) | 2018-12-20 |
US11391723B2 (en) | 2022-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230007916A1 (en) | Analyte monitoring system and methods of use | |
US11633127B2 (en) | Methods, devices, and systems related to analyte monitoring | |
US9320468B2 (en) | Analyte sensor with time lag compensation | |
US20180045707A1 (en) | Analyte Sensor with Lag Compensation | |
US20200146634A1 (en) | Methods of Lag-Compensation for Analyte Measurements, and Devices Related Thereto | |
US20190035493A1 (en) | Methods of analyte monitoring, and devices and systems related thereto | |
US10028686B2 (en) | Methods for generating hybrid analyte level output, and devices and systems related thereto | |
CN113261065A (en) | Systems, devices, and methods for improving meal and therapy interfaces in analyte monitoring systems | |
US20230225615A1 (en) | Systems, devices, and methods for improved analyte sensor accuracy and fault detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT DIABETES CARE INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARPER, WESLEY SCOTT;BUDIMAN, ERWIN SATRYA;DONIGER, KENNETH J.;AND OTHERS;SIGNING DATES FROM 20130228 TO 20130312;REEL/FRAME:061033/0721 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |